AU2017203307A1 - Osmotic mediated release synthetic nanocarriers - Google Patents
Osmotic mediated release synthetic nanocarriers Download PDFInfo
- Publication number
- AU2017203307A1 AU2017203307A1 AU2017203307A AU2017203307A AU2017203307A1 AU 2017203307 A1 AU2017203307 A1 AU 2017203307A1 AU 2017203307 A AU2017203307 A AU 2017203307A AU 2017203307 A AU2017203307 A AU 2017203307A AU 2017203307 A1 AU2017203307 A1 AU 2017203307A1
- Authority
- AU
- Australia
- Prior art keywords
- synthetic nanocarriers
- dosage form
- osmotically active
- active agent
- nanocarriers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002539 nanocarrier Substances 0.000 title claims abstract description 487
- 230000003204 osmotic effect Effects 0.000 title claims abstract description 90
- 230000001404 mediated effect Effects 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 claims abstract description 131
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000002552 dosage form Substances 0.000 claims description 97
- 239000013543 active substance Substances 0.000 claims description 96
- 108091007433 antigens Proteins 0.000 claims description 88
- 102000036639 antigens Human genes 0.000 claims description 88
- 239000000427 antigen Substances 0.000 claims description 86
- 229920000642 polymer Polymers 0.000 claims description 59
- 150000001720 carbohydrates Chemical class 0.000 claims description 58
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 108091034117 Oligonucleotide Proteins 0.000 claims description 54
- 239000002671 adjuvant Substances 0.000 claims description 48
- 239000003795 chemical substances by application Substances 0.000 claims description 47
- -1 NaPC>4 Chemical compound 0.000 claims description 46
- 239000000839 emulsion Substances 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 230000003308 immunostimulating effect Effects 0.000 claims description 30
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 239000000126 substance Substances 0.000 claims description 25
- 235000014633 carbohydrates Nutrition 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 238000012545 processing Methods 0.000 claims description 18
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 16
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 15
- 239000003981 vehicle Substances 0.000 claims description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 239000003446 ligand Substances 0.000 claims description 10
- 239000013612 plasmid Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 230000000890 antigenic effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 230000008014 freezing Effects 0.000 claims description 9
- 229920000058 polyacrylate Polymers 0.000 claims description 9
- 239000003053 toxin Substances 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229920001282 polysaccharide Polymers 0.000 claims description 8
- 239000005017 polysaccharide Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 8
- 230000001960 triggered effect Effects 0.000 claims description 8
- 208000035473 Communicable disease Diseases 0.000 claims description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- 239000002738 chelating agent Substances 0.000 claims description 7
- 239000000499 gel Substances 0.000 claims description 7
- 238000010979 pH adjustment Methods 0.000 claims description 7
- 229920000193 polymethacrylate Polymers 0.000 claims description 7
- 229920005862 polyol Polymers 0.000 claims description 7
- 150000003077 polyols Chemical class 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 239000003381 stabilizer Substances 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 229920000954 Polyglycolide Polymers 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- 239000000412 dendrimer Substances 0.000 claims description 6
- 229920000736 dendritic polymer Polymers 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- 108091023037 Aptamer Proteins 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920002292 Nylon 6 Polymers 0.000 claims description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 238000000137 annealing Methods 0.000 claims description 5
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 229960005070 ascorbic acid Drugs 0.000 claims description 5
- 239000006172 buffering agent Substances 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 150000002016 disaccharides Chemical class 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000009368 gene silencing by RNA Effects 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 108091070501 miRNA Proteins 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 150000002772 monosaccharides Chemical class 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 239000004055 small Interfering RNA Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 102000043129 MHC class I family Human genes 0.000 claims description 4
- 108091054437 MHC class I family Proteins 0.000 claims description 4
- 239000000370 acceptor Substances 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 229940087168 alpha tocopherol Drugs 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 230000001028 anti-proliverative effect Effects 0.000 claims description 4
- 239000003146 anticoagulant agent Substances 0.000 claims description 4
- 229940127219 anticoagulant drug Drugs 0.000 claims description 4
- 230000010100 anticoagulation Effects 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000005515 coenzyme Substances 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 4
- 231100000317 environmental toxin Toxicity 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 238000001415 gene therapy Methods 0.000 claims description 4
- 239000000383 hazardous chemical Substances 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 4
- 150000002678 macrocyclic compounds Chemical class 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 4
- 229960000984 tocofersolan Drugs 0.000 claims description 4
- 150000004043 trisaccharides Chemical class 0.000 claims description 4
- 239000002076 α-tocopherol Substances 0.000 claims description 4
- 235000004835 α-tocopherol Nutrition 0.000 claims description 4
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 102000043131 MHC class II family Human genes 0.000 claims description 3
- 108091054438 MHC class II family Proteins 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 208000026278 immune system disease Diseases 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 239000000243 solution Substances 0.000 description 74
- 239000000203 mixture Substances 0.000 description 65
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 59
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 39
- 239000002105 nanoparticle Substances 0.000 description 28
- 229960002715 nicotine Drugs 0.000 description 25
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 25
- 230000003993 interaction Effects 0.000 description 24
- 210000003719 b-lymphocyte Anatomy 0.000 description 23
- 239000002245 particle Substances 0.000 description 23
- 239000000725 suspension Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 239000000463 material Substances 0.000 description 22
- 239000002609 medium Substances 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 238000011068 loading method Methods 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000008188 pellet Substances 0.000 description 13
- 239000008363 phosphate buffer Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 102000002689 Toll-like receptor Human genes 0.000 description 10
- 108020000411 Toll-like receptor Proteins 0.000 description 10
- 230000004888 barrier function Effects 0.000 description 10
- 230000008878 coupling Effects 0.000 description 10
- 238000010168 coupling process Methods 0.000 description 10
- 238000005859 coupling reaction Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 10
- 239000012736 aqueous medium Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 9
- 239000011159 matrix material Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000004626 polylactic acid Substances 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 150000004713 phosphodiesters Chemical group 0.000 description 6
- 150000004804 polysaccharides Chemical class 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 5
- 238000002296 dynamic light scattering Methods 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 239000013554 lipid monolayer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000002357 osmotic agent Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000009987 spinning Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001082241 Lythrum hyssopifolia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical group NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 125000005313 fatty acid group Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000011859 microparticle Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 229920002721 polycyanoacrylate Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229950010550 resiquimod Drugs 0.000 description 3
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 3
- 150000003384 small molecules Chemical group 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 102100030886 Complement receptor type 1 Human genes 0.000 description 2
- 102100032768 Complement receptor type 2 Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000305071 Enterobacterales Species 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 2
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 description 2
- 102000002227 Interferon Type I Human genes 0.000 description 2
- 108010014726 Interferon Type I Proteins 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000012064 NLR Proteins Human genes 0.000 description 2
- 108091005686 NOD-like receptors Proteins 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920002732 Polyanhydride Polymers 0.000 description 2
- 229920001273 Polyhydroxy acid Polymers 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 241001222774 Salmonella enterica subsp. enterica serovar Minnesota Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241000607762 Shigella flexneri Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004147 Sorbitan trioleate Substances 0.000 description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011247 coating layer Substances 0.000 description 2
- 108010047295 complement receptors Proteins 0.000 description 2
- 102000006834 complement receptors Human genes 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000009881 electrostatic interaction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N ethyl stearic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 229940124669 imidazoquinoline Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Natural products CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 2
- AOHAPDDBNAPPIN-UHFFFAOYSA-N myristicinic acid Natural products COC1=CC(C(O)=O)=CC2=C1OCO2 AOHAPDDBNAPPIN-UHFFFAOYSA-N 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000002086 nanomaterial Substances 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 239000004632 polycaprolactone Substances 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 229920006324 polyoxymethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229940068977 polysorbate 20 Drugs 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 description 2
- 229960000391 sorbitan trioleate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 1
- FBFJOZZTIXSPPR-UHFFFAOYSA-N 1-(4-aminobutyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical class C1=CC=CC2=C(N(C(COCC)=N3)CCCCN)C3=C(N)N=C21 FBFJOZZTIXSPPR-UHFFFAOYSA-N 0.000 description 1
- FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- VKNASXZDGZNEDA-UHFFFAOYSA-N 2-cyanoethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC#N VKNASXZDGZNEDA-UHFFFAOYSA-N 0.000 description 1
- SFPNZPQIIAJXGL-UHFFFAOYSA-N 2-ethoxyethyl 2-methylprop-2-enoate Chemical class CCOCCOC(=O)C(C)=C SFPNZPQIIAJXGL-UHFFFAOYSA-N 0.000 description 1
- RMZNXRYIFGTWPF-UHFFFAOYSA-N 2-nitrosoacetic acid Chemical compound OC(=O)CN=O RMZNXRYIFGTWPF-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- RHKWIGHJGOEUSM-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinoline Chemical class C1=CN=C2C(N=CN3)=C3C=CC2=C1 RHKWIGHJGOEUSM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 description 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- AFWTZXXDGQBIKW-UHFFFAOYSA-N C14 surfactin Natural products CCCCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 AFWTZXXDGQBIKW-UHFFFAOYSA-N 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical class [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010040721 Flagellin Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241001460678 Napo <wasp> Species 0.000 description 1
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 description 1
- 108010019759 OVA 323-339 Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001165 Poly(4-hydroxy-l-proline ester Polymers 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001135759 Sphingomonas sp. Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 1
- 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- VUBTYKDZOQNADH-UHFFFAOYSA-N acetyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)=O VUBTYKDZOQNADH-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical class N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000002355 alkine group Chemical group 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000961 alloantigen Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Chemical group NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000010461 azide-alkyne cycloaddition reaction Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical group 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229930183167 cerebroside Natural products 0.000 description 1
- 150000001784 cerebrosides Chemical class 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000002575 chemical warfare agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000012650 click reaction Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000000409 cytokine receptor agonist Substances 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 1
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- LQJBNNIYVWPHFW-QXMHVHEDSA-N gadoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCC(O)=O LQJBNNIYVWPHFW-QXMHVHEDSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008102 immune modulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QAPAPLIQQTVEJZ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]ethanamine Chemical compound CCNCC1=CC=CC(F)=C1 QAPAPLIQQTVEJZ-UHFFFAOYSA-N 0.000 description 1
- 239000005543 nano-size silicon particle Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000575 polymersome Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001299 polypropylene fumarate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910021426 porous silicon Inorganic materials 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 229920013730 reactive polymer Polymers 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000015227 regulation of liquid surface tension Effects 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- NJGWOFRZMQRKHT-UHFFFAOYSA-N surfactin Natural products CC(C)CCCCCCCCCC1CC(=O)NC(CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-UHFFFAOYSA-N 0.000 description 1
- NJGWOFRZMQRKHT-WGVNQGGSSA-N surfactin C Chemical compound CC(C)CCCCCCCCC[C@@H]1CC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)O1 NJGWOFRZMQRKHT-WGVNQGGSSA-N 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000010977 unit operation Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Inorganic Chemistry (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
Abstract
This invention relates, at least in part, to osmotic mediated release barrier-free synthetic nanocarriers and methods of production and use. See Fig. 2. WO 2012/135010 PCT/US2012/030314 45% *n 44~ 35% .. o 30% 4-1 20% 15% 0 S10% -'5% 0% 0 100 200 300 400 Calculated Osmolality (mOsm/kg) Fig. 1 Release Medium Osmolality (mOsm/kg) Fig. 2
Description
PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
OSMOTIC MEDIATED RELEASE SYNTHETIC NANOCARRIERS
RELATED APPLICATIONS
This application claims the benefit under 35 U.S.5 C. § 119 of United States 5 provisional application 61/467,595, filed March 25, 2011, the entire contents of which are incorporated herein by reference.
FIELD OF THE INVENTION
This invention relates, at least in part, to osmotic mediated release barrier-free 10 synthetic nanocarriers and methods of production and use.
BACKGROUND OF THE INVENTION 20
Safe and effective delivery to patients of osmotically active agents, such as isolated nucleic acids or isolated peptides, is a current therapeutic limitation. Liposomes, microparticles, nanoparticles, polymersomes, solid-lipid-particles, and the like have been utilized in an attempt to provide for delivery of osmotically active agents. Many of these systems conventionally utilize positively-charged surfactants or polymers and/or a durable diffusion-impermeable barrier to secure the osmotically active agent to/within the carrier. These systems tend to be limited in their utility because of potential toxicity of the cationic elements and/or by low rates of release of the osmotically active agent from the system. The low rates of release may be attributed to the cationic agent, the relatively low % w/w loading of the system, or the nature of the diffusive barrier.
Therefore, what is needed are compositions and methods that address the problems in the art as noted above. 25
SUMMARY OF THE INVENTION
In one aspect, a dosage form comprising osmotic mediated release barrier-free synthetic nanocarriers comprising an encapsulated osmotically active agent is provided. In one embodiment, the dosage form further comprises a vehicle having an osmolality of 200-500 mOsm/kg. In one embodiment, the osmotic mediated release barrier-free synthetic nanocarriers comprise pH triggered osmotic mediated release barrier-free synthetic nanocarriers. 1 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
In another aspect, a method comprising forming osmotic mediated release barrier-free synthetic nanocarriers that comprise an osmotically active agent in an environment having an osmolality ranging from 200-500 mOsm/kg; and maintaining the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment having an osmolality 5 ranging from 200-500 mOsm/kg is provided. In one embodiment, the environment in which the osmotic mediated release barrier-free synthetic nanocarriers are formed, and the environment in which the osmotic mediated release barrier-free synthetic nanocarriers are maintained, are the same. In one embodiment, the method further comprises processing the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment 10 having an osmolality ranging from 200-500 mOsm/kg. In one embodiment, the processing comprises: washing the synthetic nanocarriers, centrifuging the synthetic nanocarriers, filtering the synthetic nanocarriers, concentrating or diluting the synthetic nanocarriers, freezing the synthetic nanocarriers, drying the synthetic nanocarriers, combining the synthetic nanocarriers with other synthetic nanocarriers or with additive agents or 15 excipients, adjusting the pH or buffer environment of the synthetic nanocarriers, entrapping the synthetic nanocarriers in a gel or high-viscosity medium, resuspending the synthetic nanocarriers, surface modifying the synthetic nanocarriers covalently or by physical processes such as coating or annealing, impregnating or doping the synthetic nanocarriers with active agents or excipients, sterilizing the synthetic nanocarriers, reconstituting the 20 synthetic nanocarriers for administration, or combinations of any of the above. In one embodiment, the method further comprises storing the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg. In one embodiment, the method further comprises formulating the formed osmotic mediated release barrier-free synthetic nanocarriers into a dosage form that 25 maintains the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg.
In another aspect, a process for producing a dosage form comprising osmotic mediated release barrier-free synthetic nanocarriers comprising the method steps as defined in any of the methods provided is provided. 30 In another aspect, a dosage form comprising any of the osmotic mediated release barrier-free synthetic nanocarriers is provided. Such synthetic nanocarriers may be made 2 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 according to any of the methods or processes provided. Such synthetic nanocarriers may be produced or obtainable by any of the methods or processes provided.
In another aspect, a lyophilized dosage form comprising lyophilized osmotic mediated release barrier-free synthetic nanocarriers comprising an encapsulated osmotically 5 active agent; and lyophilizing agents that provide a vehicle having an osmolality of 200-500 mOsm/kg upon reconstitution of the lyophilized dosage form is provided. In one embodiment, the lyophilizing agents comprise comprise salts and buffering agents, simple or complex carbohydrates, polyols, pH adjustment agents, chelating and antioxidant agents, stabilizers and preservatives, or surfactants. In one embodiment, the salts and buffering 10 agents comprise NaCl, NaPC>4, or Tris, the simple or complex carbohydrates comprise sucrose, dextrose, dextran, or carboxymethyl cellulose, the polyols comprise mannitol, sorbitol, glycerol, or polyvinyl alcohol, the pH adjustment agents comprise HC1, NaOH, or sodium citrate, the chelating and antioxidant agents comprise EDTA, ascorbic acid, or alpha-tocopherol, the stabilizers and preservatives comprise gelatin, glycine, histidine, or 15 benzyl alcohol, and/or the surfactants comprise polysorbate 80, sodium deoxycholate, or Triton X-100. In one embodiment, the osmotic mediated release barrier-free synthetic nanocarriers comprise pH triggered osmotic mediated release barrier-free synthetic nanocarriers.
In another aspect, a method comprising providing osmotic mediated release barrier-20 free synthetic nanocarriers that comprise an osmotically active agent in an environment having an osmolality ranging from 200-500 mOsm/kg; and administering the osmotic mediated release barrier-free synthetic nanocarriers to a subject is provided. In one embodiment, the method further comprises processing the formed osmotic mediated release barrier-free synthetic nanocarriers only in environments having an osmolality ranging from 25 200-500 mOsm/kg. In one embodiment, the processing comprises: washing the synthetic nanocarriers, centrifuging the synthetic nanocarriers, filtering the synthetic nanocarriers, concentrating or diluting the synthetic nanocarriers, freezing the synthetic nanocarriers, drying the synthetic nanocarriers, combining the synthetic nanocarriers with other synthetic nanocarriers or with additive agents or excipients, adjusting the pH or buffer environment of 30 the synthetic nanocarriers, entrapping the synthetic nanocarriers in a gel or high-viscosity medium, resuspending the synthetic nanocarriers, surface modifying the synthetic nanocarriers covalently or by physical processes such as coating or annealing, impregnating 3 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 or doping the synthetic nanocarriers with active agents or excipients, sterilizing the synthetic nanocarriers, reconstituting the synthetic nanocarriers for administration, or combinations of any of the above. In another embodiment, the method further comprises storing the formed osmotic mediated release barrier-free synthetic nanocarriers in an 5 environment having an osmolality ranging from 200-500 mOsm/kg. In another embodiment, the method further comprises formulating the formed osmotic mediated release barrier-free synthetic nanocarriers into a dosage form that maintains the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg. 10 In another aspect, a method of administering any of the compositions or dosage forms provided to a subject is provided. In one embodiment, the subject is in need thereof. In one embodiment, the subject has cancer, an infectious disease, a metabolic disease, a degenerative disease, an autoimmune disease, or an inflammatory disease. In one embodiment, the subject has an addiction. In one embodiment, the subject has been 15 exposed to a toxin. In one embodiment, the composition or dosage form is in an amount effective to treat the subject.
In another aspect, a kit, comprising any of the compositions or dosage forms provided is provided. In one embodiment, the dosage form is a lyophilized dosage form. In one embodiment, the kit further comprises instructions for use and/or mixing. In one 20 embodiment, the kit further comprises an agent for reconstitution or a pharmaceutically acceptable carrier.
In another aspect, any of the compositions or dosage forms provided may be for use in therapy or prophylaxis. In another aspect, any of the compositions or dosage forms provided may be for use in any of the methods provided. In another aspect, any of the 25 compositions or dosage forms provided may be for use in a method of modulating, for example, inducing, enhancing, suppressing, directing, or redirecting, an immune response. In another aspect, any of the compositions or dosage forms provided may be for use in a method of treating or preventing cancer, an infectious disease, a metabolic disease, a degenerative disease, an autoimmune disease, an inflammatory disease, an immunological 30 disease, an addiction, or a condition resulting from the exposure to a toxin, hazardous substance, environmental toxin, or other harmful agent. In another aspect, any of the compositions or dosage forms provided may be for use in a method of therapy or 4 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 prophylaxis comprising administration by a subcutaneous, intramuscular, intradermal, oral, intranasal, transmucosal, sublingual, rectal, ophthalmic, transdermal, transcutaneous route or by a combination of these routes. In another aspect, use of any of the compositions or dosage forms provided for the manufacture of a medicament for use in any of the methods 5 provided is provided.
In one embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 2 weight percent, based on the total theoretical weight of the synthetic nanocarriers. In another embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 3 weight percent, based on the total 10 theoretical weight of the synthetic nanocarriers. In another embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 4 weight percent, based on the total theoretical weight of the synthetic nanocarriers. In another embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 5 weight percent, based on the total theoretical weight of the synthetic nanocarriers. In 15 another embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 6 weight percent, based on the total theoretical weight of the synthetic nanocarriers. In another embodiment, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 7 weight percent, based on the total theoretical weight of the synthetic nanocarriers. In another embodiment, the osmotically active agent is 20 present in the synthetic nanocarriers in an amount of about 8 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
In one embodiment, the osmotically active agent comprises an isolated nucleic acid, a polymer, an isolated peptide, an isolated saccharide, macrocycle, or ions, cofactors, coenzymes, ligands, hydrophobically-paired agents, or hydrogen-bond donors or acceptors 25 of any of the above. In one embodiment, the isolated nucleic acid comprises an immunostimulatory nucleic acid, immunostimulatory oligonucleotides, small interfering RNA, RNA interference oligonucleotides, RNA activating oligonucleotides, micro RNA oligonucleotides, antisense oligonucleotides, aptamers, gene therapy oligonucleotides, natural form plasmids, non-natural plasmids, chemically modified plasmids, chimeras that 30 include oligonucleotide-based sequences, and combinations of any of the above. In another embodiment, the polymer comprises osmotically active dendrimers, polylactic acids, polyglycolic acids, poly lactic-co-glycolic acids, polycaprolactams, polyethylene glycols, 5 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 polyacrylates, polymethacrylates, and co-polymers and/or combinations of any of the above. In another embodiment, the isolated peptide comprises osmotically active immunomodulatory peptides, MHC Class I or MHC Class Π binding peptides, antigenic peptides, hormones and hormone mimetics, ligands, antibacterial and antimicrobial 5 peptides, anti-coagulation peptides, and enzyme inhibitors. In another embodiment, the isolated saccharide comprises osmotically active antigenic saccharides, lipopolysaccharides, protein or peptide mimetic saccharides, cell surface targeting saccharides, anticoagulants, anti-inflammatory saccharides, anti-proliferative saccharides, including their natural and modified forms, monosaccharides, disaccharides, trisaccharides, oligosaccharides, or 10 polysaccharides.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 demonstrates that oligonucleotide losses were driven by media osmolality for an already-formed and loaded nanocarrier. 15 Fig. 2 shows the percent release versus osmolality.
DETAILED DESCRIPTION OF THE INVENTION
Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified materials or process parameters as such 20 may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting of the use of alternative terminology to describe the present invention.
All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety for all purposes. 25 As used in this specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the content clearly dictates otherwise. For example, reference to "a polymer" includes a mixture of two or more such molecules or a mixture of differing molecular weights of a single polymer species, reference to "a synthetic nanocarrier" includes a mixture of two or more such synthetic nanocarriers or a plurality of 30 such synthetic nanocarriers, reference to "a DNA molecule" includes a mixture of two or more such DNA molecules or a plurality of such DNA molecules, reference to “an 6 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 adjuvant” includes a mixture of two or more such materials or a plurality of adjuvant molecules, and the like.
As used herein, the term “comprise” or variations thereof such as “comprises” or “comprising” are to be read to indicate the inclusion of any recited integer (e.g. a feature, 5 element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers. Thus, as used herein, the term “comprising” is inclusive and does not exclude additional, unrecited integers or method/process steps. 10 In embodiments of any of the compositions and methods provided herein, “comprising” may be replaced with “consisting essentially of “or “consisting of’. The phrase “consisting essentially of’ is used herein to require the specified integer(s) or steps as well as those which do not materially affect the character or function of the claimed invention. As used herein, the term “consisting” is used to indicate the presence of the 15 recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) alone.
A. INTRODUCTION 20 The inventors have unexpectedly and surprisingly discovered that the problems and limitations noted above can be overcome by practicing the invention disclosed herein. In particular, the inventors have unexpectedly discovered that it is possible to provide compositions, and related methods, that comprise dosage forms comprising osmotic mediated release barrier-free synthetic nanocarriers comprising an encapsulated osmotically 25 active agent. The invention also relates to methods comprising: forming osmotic mediated release barrier-free synthetic nanocarriers that comprise an osmotically active agent in an environment having an osmolality ranging from 200-500 mOsm/kg; and maintaining the formed osmotic mediated release barrier-free synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg. The invention further relates to 30 lyophilized dosage forms comprising: lyophilized osmotic mediated release barrier-free synthetic nanocarriers comprising an encapsulated osmotically active agent; and lyophilizing agents that provide a vehicle having an osmolality of 200-500 mOsm/kg upon 7 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 reconstitution of the lyophilized dosage form. The invention further relates to methods comprising: providing osmotic mediated release barrier-free synthetic nanocarriers that comprise an osmotically active agent in an environment having an osmolality ranging from 200-500 mOsm/kg; and administering the osmotic mediated release barrier-free synthetic 5 nanocarriers to a subject.
The invention described herein provides synthetic nanocarriers that do not rely on positive charge to retain osmotically active agents. Such synthetic nanocarriers further provide for rapid release of osmotically active agent(s) from nanocarriers at a relatively high weight percent loading. Mammals, and most other known organisms, maintain a 10 physiologic osmolality around 275-300 mOsm/kg. Slightly hypotonic media and hypertonic media and suspensions of appropriate volume can be administered by most routes, but the range of ~ 200-500 mOsm/kg is preferable as part of the invention to avoid osmolality-driven side effects (e.g., pain, hemolysis). For this reason, in a preferred embodiment, inventive dosage forms are provided that comprise synthetic nanocarriers 15 suspension at near-physiologic osmolality. Once administered (by injection, inhalation, topical application, oral, or other route) the synthetic nanocarriers are preferably deployed into an environment having physiologic-normal osmolality.
Among other aspects, what was surprisingly discovered was the critical role played by balance of osmotic forces in generating and sustaining inventive synthetic nanocarriers 20 comprising osmotically active agents. In embodiments, a steady-state, or near steady-state, condition of the synthetic nanocarriers is preferred during the dosage preparation and for at least part of the period of exposure to the body. Accordingly, the synthetic nanocarriers must be able to sufficiently balance the resulting osmotic pressure gradient across the synthetic nanocarriers without losing essential attributes (e.g., integrity or loading of 25 osmotically active agent(s)). In the presence of an osmotic imbalance, if the synthetic nanocarriers cannot sustain the imbalance and the encapsulated osmotically active agent is at an osmolality greater than the surrounding medium, uncontrolled efflux of the osmotically active agent or loss of nanocarrier structural integrity may occur. Such occurrences result in synthetic nanocarriers having poor performance. 30 For instance, there is a body of literature regarding the entrapment, encapsulation, and adsorption of nucleic acids in a micro or nanocarrier form. Given the obvious size, water solubility, and net negative charge of nucleic acids, it is unsurprising that the 8 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 literature largely addresses the use of charge attraction (e.g., cationic chitosan, poly-lysine, or cationic lipids) and diffusive barriers (e.g., intact polymer or lipid walls) to retain oligonucleotide with the carrier. Typical published data is characterized by nanoparticles having 0.1 to 1.0% w/w oligonucleotide loading, a burst release of anywhere from 10 to 5 80% of the initial load, and then a gradual release of 10-50% of the remaining entrapped oligonucleotide over 5 days to 6 weeks (Malyala et al., 2008; Roman et al., 2008; Diwan et. al 2002; Gvili et al., 2007). These results translate to steady release rates of ~ 0.002 to 1 ug-ON/mg-NC/l-day.
In contrast, there does not appear to be any discussion in the literature of the 10 important role that a balance of osmotic gradients can play in the retention and delivery of nucleic acids or other osmotically active agents in the absence of a cationic or barrier structural component in a synthetic nanocarrier. An advantage of the inventive dosage forms is that it is possible to achieve relatively high loadings of osmotically active agent(s) in the recited synthetic nanocarriers, thus enabling relatively high release rates of 15 osmotically active agent(s) from the synthetic nanocarriers. The ability to provide relatively high release rates of osmotically active agents from synthetic nanocarriers can be important to function. For instance, using model systems, immunization studies demonstrated a correlation between the antibody titers achieved by a CpG-nanocarrier preparation and the rate of CpG release from that nanocarrier in an in vitro test. Synthetic nanocarriers 20 characterized by post-burst release of > 10 pg-CpG/mg-nanocarrier-24h demonstrated potency in supporting high titers in these studies. It is also observed that increasing the specific release rate, up to at least 30 pg-CpG/mg-nanocarrier-24h, resulted in increasing antibody titers.
The invention will now be described in more detail below. 25
B. DEFINITIONS “Adjuvant” means an agent that does not constitute a specific antigen, but boosts the strength and longevity of an immune response to a concomitantly administered antigen. In embodiments, adjuvants may also be osmotically active agents. Adjuvants may include, 30 but are not limited to, stimulators of pattern recognition receptors, such as Toll-like receptors, RIG-1 and NOD-like receptors (NLR), mineral salts, such as alum, alum combined with monphosphoryl lipid (MPL) A of Enterobacteria, such as Escherihia coli, 9 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017
Salmonella Minnesota, Salmonella typhimurium, or Shigella flexneri or specifically with MPL® (AS04), MPL A of above-mentioned bacteria separately, saponins, such as QS-21,Quil-A, ISCOMs, ISCOMATRIX™, emulsions such as MF59™, Montanide® ISA 51 and ISA 720, AS02 (QS21+squalene+ MPL®), liposomes and liposomal formulations such 5 as AS01, synthesized or specifically prepared microparticles and microcarriers such as bacteria-derived outer membrane vesicles (OMV) of N. gonorrheae, Chlamydia trachomatis and others, or chitosan particles, depot-forming agents, such as Pluronic® block copolymers, specifically modified or prepared peptides, such as muramyl dipeptide, aminoalkyl glucosaminide 4-phosphates, such as RC529, or proteins, such as bacterial 10 toxoids or toxin fragments.
In embodiments, adjuvants comprise agonists for pattern recognition receptors (PRR), including, but not limited to Toll-Like Receptors (TLRs), specifically TLRs 2, 3, 4, 5, 7, 8, 9 and/or combinations thereof. In other embodiments, adjuvants comprise agonists for Toll-Like Receptors 3, agonists for Toll-Like Receptors 7 and 8, or agonists for Toll-15 Like Receptor 9; preferably the recited adjuvants comprise imidazoquinolines; such as R848; adenine derivatives, such as those disclosed in US patent 6,329,381 (Sumitomo Pharmaceutical Company), US Published Patent Application 2010/0075995 to Biggadike et al., W02010/018134, WO 2010/018133, WO 2010/018132, WO 2010/018131, WO 2010/018130 and WO 2008/101867 to Campos et al.; immunostimulatory DNA; or 20 immuno stimulatory RNA. In specific embodiments, synthetic nanocarriers incorporate as adjuvants compounds that are agonists for toll-like receptors (TLRs) 7 & 8 (“TLR 7/8 agonists”). Of utility are the TLR 7/8 agonist compounds disclosed in US Patent 6,696,076 to Tomai et al., including but not limited to imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline 25 amines. Preferred adjuvants comprise imiquimod and resiquimod (also known as R848). In specific embodiments, an adjuvant may be an agonist for the DC surface molecule CD40.
In certain embodiments, to stimulate immunity rather than tolerance, a synthetic nanocarrier incorporates an adjuvant that promotes DC maturation (needed for priming of naive T cells) and the production of cytokines, such as type I interferons, which promote antibody immune 30 responses. In embodiments, adjuvants also may comprise immunostimulatory RNA molecules, such as but not limited to dsRNA, poly I:C or poly I:poly C12U (available as Ampligen ®, both poly I:C and poly I:polyC12U being known as TLR3 stimulants), and/or 10 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 those disclosed in F. Heil et al., “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8” Science 303(5663), 1526-1529 (2004); J. Vollmer et al., “Immune modulation by chemically modified ribonucleosides and oligoribonucleotides” WO 2008033432 A2; A. Forsbach et al., “Immunostimulatory oligoribonucleotides 5 containing specific sequence motif(s) and targeting the Toll-like receptor 8 pathway” WO 2007062107 A2; E. Uhlmann et al., “Modified oligoribonucleotide analogs with enhanced immunostimulatory activity” U.S. Pat. Appl. Publ. US 2006241076; G. Lipford et al., “Immunostimulatory viral RNA oligonucleotides and use for treating cancer and infections” WO 2005097993 A2; G. Lipford et al., “Immunostimulatory G,U-containing 10 oligoribonucleotides, compositions, and screening methods” WO 2003086280 A2. In some embodiments, an adjuvant may be a TLR-4 agonist, such as bacterial lipopolysacccharide (LPS), VSV-G, and/or HMGB-1. In some embodiments, adjuvants may comprise TLR-5 agonists, such as flagellin, or portions or derivatives thereof, including but not limited to those disclosed in US Patents 6,130,082, 6,585,980, and 7,192,725. In specific 15 embodiments, synthetic nanocarriers incorporate a ligand for Toll-like receptor (TLR)-9, such as immunostimulatory DNA molecules comprising CpGs, which induce type I interferon secretion, and stimulate T and B cell activation leading to increased antibody production and cytotoxic T cell responses (Krieg et al., CpG motifs in bacterial DNA trigger direct B cell activation. Nature. 1995. 374:546-549; Chu et al. CpG oligodeoxynucleotides 20 act as adjuvants that switch on T helper 1 (Thl) immunity. J. Exp. Med. 1997. 186:1623-1631; Lipford et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur. J. Immunol. 1997. 27:2340-2344; Roman et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.. Nat. Med. 1997. 3:849-854; Davis et al. CpG DNA is a potent 25 enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 1998. 160:870-876; Lipford et al., Bacterial DNA as immune cell activator. Trends Microbiol. 1998. 6:496-500; US Patent 6,207,646 to Krieg et al.; US Patent 7,223,398 to Tuck et al.; US Patent 7,250,403 to Van Nest et al.; or US Patent 7,566,703 to Krieg et al. 30 In some embodiments, adjuvants may be proinflammatory stimuli released from necrotic cells (e.g., urate crystals). In some embodiments, adjuvants may be activated components of the complement cascade (e.g., CD21, CD35, etc.). In some embodiments, 11 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 adjuvants may be activated components of immune complexes. The adjuvants also include complement receptor agonists, such as a molecule that binds to CD21 or CD35. In some embodiments, the complement receptor agonist induces endogenous complement opsonization of the synthetic nanocarrier. In some embodiments, adjuvants are cytokines, 5 which are small proteins or biological factors (in the range of 5 kD - 20 kD) that are released by cells and have specific effects on cell-cell interaction, communication and behavior of other cells. In some embodiments, the cytokine receptor agonist is a small molecule, antibody, fusion protein, or aptamer. "Administering" or "administration" means providing a material to a subject in a 10 manner that is pharmacologically useful. “Amount effective” is any amount of a composition that produces one or more desired immune responses. This amount can be for in vitro or in vivo purposes. For in vivo purposes, the amount can be one that a health practitioner would believe may have a clinical benefit for a subject in need thereof. In embodiments, therefore, an amount effective is one 15 that a health practitioner would believe may generate an antibody response against any antigen(s) of the inventive compositions provided herein. Effective amounts can be monitored by routine methods. An amount that is effective to produce one or more desired immune responses can also be an amount of a composition provided herein that produces a desired therapeutic endpoint or a desired therapeutic result. Therefore, in other 20 embodiments, the amount effective in one that a clinician would believe would provide a therapeutic benefit (including a prophylactic benefit) to a subject provided herein. Such subjects include those that have or are at risk of having cancer, an infection or infectious disease. Such a subjects include any subject that has or is at risk of having any of the diseases, conditions and/or disorders provide herein. 25 Amounts effective will depend, of course, on the particular subject being treated; the severity of a condition, disease or disorder; the individual patient parameters including age, physical condition, size and weight; the duration of the treatment; the nature of concurrent therapy (if any); the specific route of administration and like factors within the knowledge and expertise of the health practitioner. These factors are well known to those of ordinary 30 skill in the art and can be addressed with no more than routine experimentation. It is generally preferred that a “maximum dose” be used, that is, the highest safe dose according to sound medical judgment. It will be understood by those of ordinary skill in the art, 12 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 however, that a patient may insist upon a lower dose or tolerable dose for medical reasons, psychological reasons or for virtually any other reasons. The antigen(s) of any of the inventive compositions provided herein can in embodiments be in an amount effective. “Antigen” means a B cell antigen or T cell antigen. In embodiments, antigens are 5 coupled to the synthetic nanocarriers. In other embodiments, antigens are not coupled to the synthetic nanocarriers. In embodiments antigens are coadministered with the synthetic nanocarriers. In other embodiments antigens are not coadministered with the synthetic nanocarriers. “Type(s) of antigens” means molecules that share the same, or substantially the same, antigenic characteristics. 10 “B cell antigen” means any antigen that is or recognized by and triggers an immune response in a B cell (e.g., an antigen that is specifically recognized by a B cell receptor on a B cell). In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other embodiments, the T cell antigen is not also a B cell antigen. B cell antigens include, but are not limited to proteins, peptides, small molecules, and carbohydrates. In some 15 embodiments, the B cell antigen comprises a non-protein antigen (i.e., not a protein or peptide antigen). In some embodiments, the B cell antigen comprises a carbohydrate associated with an infectious agent. In some embodiments, the B cell antigen comprises a glycoprotein or glycopeptide associated with an infectious agent. The infectious agent can be a bacterium, virus, fungus, protozoan, or parasite. In some embodiments, the B cell 20 antigen comprises a poorly immunogenic antigen. In some embodiments, the B cell antigen comprises an abused substance or a portion thereof. In some embodiments, the B cell antigen comprises an addictive substance or a portion thereof. Addictive substances include, but are not limited to, nicotine, a narcotic, a cough suppressant, a tranquilizer, and a sedative. In some embodiments, the B cell antigen comprises a toxin, such as a toxin from a 25 chemical weapon or natural sources. The B cell antigen may also comprise a hazardous environmental agent. In some embodiments, the B cell antigen comprises a self antigen. In other embodiments, the B cell antigen comprises an alloantigen, an allergen, a contact sensitizer, a degenerative disease antigen, a hapten, an infectious disease antigen, a cancer antigen, an atopic disease antigen, an autoimmune disease antigen, an addictive substance, a 30 xenoantigen, or a metabolic disease enzyme or enzymatic product thereof. “Barrier-free” means synthetic nanocarriers that lack a release rate-controlling barrier, located on or within a surface of the synthetic nanocarriers, that controls the release 13 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 rate of the encapsulated osmotically active agent from the synthetic nanocarriers into an environment surrounding the nanocarriers. In an embodiment, barrier-free synthetic nanocarriers lack a structural element the presence of which would have limited diffusion of osmotically active agents such that an osmotic pressure difference, e.g. allowing the 5 creation of an osmotic pressure difference that would lead to structural disruption of the synthetic nanocarriers, between the interior of the synthetic nanocarriers and the external environment of the synthetic nanocarriers. “Couple” or “Coupled” or “Couples” (and the like) means to chemically associate one entity (for example a moiety) with another. In some embodiments, the coupling is 10 covalent, meaning that the coupling occurs in the context of the presence of a covalent bond between the two entities. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, hydrogen bonding interactions, van der 15 Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. In embodiments, encapsulation is a form of coupling. "Dosage form" means a pharmacologically and/or immunologically active material in a medium, vehicle, carrier, or device suitable for administration to a subject. 20 “Encapsulate” or “Encapsulated” (and the like) means to couple a first entity or entities to a second entity or entities by completely or partially surrounding some or all of the first entity or entities with the second entity or entities. In embodiments, to encapsulate means to enclose within a synthetic nanocarrier, preferably enclose completely within a synthetic nanocarrier. Most or all of a substance that is encapsulated is not exposed to the 25 local environment external to the synthetic nanocarrier. In other embodiments, no more than 50%, 40%, 30%, 20%, 10% or 5% (weight/weight) is exposed to the local environment. Encapsulation is distinct from absorption, which places most or all of a substance on a surface of a synthetic nanocarrier, and leaves the substance exposed to the local environment external to the synthetic nanocarrier. 30 “Isolated nucleic acid” means a nucleic acid that may be of varying molecular weight(s) (including oligonucleotides, and polynucleic acids) that is separated from its native environment and present in sufficient quantity to permit its identification or use. An 14 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 isolated nucleic acid may be one that is (i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well 5 known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression 10 vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. Any of the nucleic acids provided herein may be isolated.
In embodiments, isolated nucleic acids comprise: immunostimulatory nucleic acids 15 such as immunostimulatory oligonucleotides (including but not limited to both DNA and RNA), small interfering RNA (siRNA), RNA interference (RNAi) oligonucleotides, RNA activating (RNAa) oligonucleotides, micro RNA (miRNA) oligonucleotides, antisense oligonucleotides, aptamers, gene therapy oligonucleotides, plasmids, including their natural and non-natural or modified chemical forms as well as chimeras that include 20 oligonucleotide-based sequences.
While oligonucelotides are macromolecules, their potential to introduce osmolality is significant. A single-strand of an oligonucleotide is a relatively high molecular-weight entity (typically > 2.4 kD at ~ 300D/nucleotide) with high water solubility (typically - 30% w/v). The osmotic contribution of oligonucleotides to a solution is primarily due to 25 counter-ions. The backbone structure of natural nucleic acids, and most unnatural analogs, contributes one negative charge per linkage between base residues, so a nucleotide of “n” monomeric units would have (n-1) associated monovalent counter-ions. For example, a 15 mM solution of a 20-base oligonucleotide with sodium counter-ions has a calculated osmolality of -300 mOsm/kg. The sodium salt of an oligonucleotide near its solubility limit 30 in water may contribute around 1000 mOsm/kg.
In a preferred embodiment, isolated nucleic acids may comprise immunostimulatory oligonucleotides(s) such as immunostimulatory DNA oligonucleotides comprising 5’ - CG 15 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 - 3” motifs or immunostimulatory RNA oligonucleotides. In an embodiment, any cytosine nucleotides (“C”) present in a 5’ - CG - 3” motif in immuno stimulatory oligonucleotides are unmethylated. C present in parts of the immuno stimulatory oligonucleotides other than in 5’ - CG - 3” motifs may be methylated, or may be unmethylated. In embodiments, the 5 recited immuno stimulatory oligonucleotides possess a phosphodiester backbone that is not modified to incorporate phosphorothioate bonds, preferably the phosphodiester backbone is free of phosphorothioate bonds. In other embodiments, the immuno stimulatory oligonucleotides’ phosphodiester backbone comprises no stabilizing chemical modifications that function to stabilize the phosphodiester backbone under physiological conditions. 10 “Isolated peptide” means a peptide that may be of varying molecular weight(s) (including peptides, oligopeptides, polypeptides, and proteins) that is separated from its native environment and present in sufficient quantity to permit its identification or use. This means, for example, the peptide may be (i) selectively produced by expression cloning or (ii) purified as by chromatography or electrophoresis. Isolated peptides may be, but need 15 not be, substantially pure. Because an isolated peptide may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the peptide may comprise only a small percentage by weight of the preparation. The peptide is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other peptides. Any of the peptides provided herein may 20 be isolated. In embodiments, isolated peptides comprise osmotically active: immunomodulatory peptides such as MHC Class I or MHC Class II binding peptides, antigenic peptides, hormones and hormone mimetics, ligands, antibacterial and antimicrobial peptides, anti-coagulation peptides, and enzyme inhibitors. “Isolated saccharide” means a saccharide that may be of varying molecular 25 weight(s) (including monosaccharides, disaccharides, trisaccharides, oligosaccharides, polysaccharides, and the like) that is separated from its native environment and present in sufficient quantity to permit its identification or use. This means, for example, the saccharide may be (i) selectively produced by synthetic methods or (ii) purified as by chromatography or electrophoresis. Isolated saccharides may be, but need not be, 30 substantially pure. Because an isolated saccharide may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the saccharide may comprise only a small percentage by weight of the preparation. The saccharide is nonetheless isolated in 16 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 that it has been separated from the substances with which it may be associated in living systems, i.e., isolated from other saccharides or peptides. Any of the saccharides provided herein may be isolated. In embodiments, isolated saccharides comprise osmotically active: antigenic saccharides (e.g., saccharides characteristic of a pathogenic or xenobiotic 5 organism), lipopolysaccharides, protein or peptide mimetic saccharides, cell surface targeting saccharides, anticoagulants, anti-inflammatory saccharides, anti-proliferative saccharides, including their natural and modified forms. “Lyophilized dosage form” means a dosage form that has undergone lyophilization. “Lyophilized osmotic mediated release barrier-free synthetic nanocarriers” means 10 osmotic mediated release barrier-free synthetic nanocarriers that have undergone lyophilization. “Lyophilizing agents” mean substances that are added to a dosage form to facilitate lyophilization of the dosage form, or reconstitution of the dosage form once lyophilized. In embodiments, lyophilizing agents may also be osmotically active agents, and may be 15 selected so as to provide a vehicle having an osmolality of 200-500 mOsm/kg upon reconstitution of the lyophilized dosage form. In embodiments, lyophilizing agents comprise salts and buffering agents (such as NaCl, NaPC>4, or Tris), simple or complex carbohydrates (such as sucrose, dextrose, dextran, or carboxymethyl cellulose), polyols (such as mannitol, sorbitol, glycerol, polyvinyl alcohol), pH adjustment agents (such as 20 HC1, NaOH, or sodium citrate), chelating and antioxidant agents (such as EDTA, ascorbic acid, alpha-tocopherol), stabilizers and preservatives (such as gelatin, glycine, histidine, or benzyl alcohol), surfactants (such as polysorbate 80, sodium deoxycholate, or Triton X-100. “Maximum dimension of a synthetic nanocarrier” means the largest dimension of a 25 nanocarrier measured along any axis of the synthetic nanocarrier. “Minimum dimension of a synthetic nanocarrier” means the smallest dimension of a synthetic nanocarrier measured along any axis of the synthetic nanocarrier. For example, for a spheroidal synthetic nanocarrier, the maximum and minimum dimension of a synthetic nanocarrier would be substantially identical, and would be the size of its diameter. Similarly, for a cuboidal 30 synthetic nanocarrier, the minimum dimension of a synthetic nanocarrier would be the smallest of its height, width or length, while the maximum dimension of a synthetic nanocarrier would be the largest of its height, width or length. In an embodiment, a 17 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is greater than 100 nm. In an embodiment, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the 5 synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or less than 5 μηι. Preferably, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is greater than 110 nm, more preferably greater than 120 nm, more preferably greater than 130 nm, and 10 more preferably still greater than 150 nm. Aspects ratios of the maximum and minimum dimensions of inventive synthetic nanocarriers may vary depending on the embodiment.
For instance, aspect ratios of the maximum to minimum dimensions of the synthetic nanocarriers may vary from 1:1 to 1,000,000:1, preferably from 1:1 to 100,000:1, more preferably from 1:1 to 1000:1, still preferably from 1:1 to 100:1, and yet more preferably 15 from 1:1 to 10:1. Preferably, a maximum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample is equal to or less than 3 μιη, more preferably equal to or less than 2 μιη, more preferably equal to or less than 1 μιη, more preferably equal to or less than 800 nm, more preferably equal to or less than 600 nm, and 20 more preferably still equal to or less than 500 nm. In preferred embodiments, a minimum dimension of at least 75%, preferably at least 80%, more preferably at least 90%, of the synthetic nanocarriers in a sample, based on the total number of synthetic nanocarriers in the sample, is equal to or greater than lOOnm, more preferably equal to or greater than 120 nm, more preferably equal to or greater than 130 nm, more preferably equal to or greater 25 than 140 nm, and more preferably still equal to or greater than 150 nm. Measurement of synthetic nanocarrier sizes is obtained by suspending the synthetic nanocarriers in a liquid (usually aqueous) media and using dynamic light scattering (DLS) (e.g. using a Brookhaven ZetaPALS instrument). For example, a suspension of synthetic nanocarriers can be diluted from an aqueous buffer into purified water to achieve a final synthetic nanocarrier 30 suspension concentration of approximately 0.01 to 0.1 mg/mL. The diluted suspension may be prepared directly inside, or transferred to, a suitable cuvette for DLS analysis. The cuvette may then be placed in the DLS, allowed to equilibrate to the controlled temperature, 18 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 and then scanned for sufficient time to aquire a stable and reproducible distribution based on appropriate inputs for viscosity of the medium and refractive indicies of the sample. The effective diameter, or mean of the distribution, is then reported. “Osmotic mediated release” means release of osmotically active agent(s) from 5 synthetic nanocarriers in a manner that satisfies the following in vitro test:
Reconstitute or dilute the dosage form to be tested into near neutral-pH aqueous media (e.g., pH 7.4) at 25°C yielding a composition with osmolality between 270-330 mOsm/kg, referred to as the Near-Physiologic Osmolality Media. Then, dilute a sample of the Near-Physiologic Osmolality Media by 9x in either purified water or 10 phosphate buffered saline media (e.g., to a final osmolality of approximately 25-35 mOsm/kg) to yield the Low-Osmolality Media. Next, measure concentration of osmotically active agent in the Near-Physiologic Osmolality Media (e.g., by OD26o for nucleic acids) and then after 2 hours of gentle agitation at 25°C in the Low-Osmolality Media. If the release (e.g., the total osmotically active agent released 15 into solution over 2 hours) is significantly greater in the Low-Osmolality Media than in the Near-Physiologic Osmolality Media (preferably ReleaseLow-osmoiaiity Media > 1.5 X ke 1 ease-Va, Physiologic Osmolality Media» ΠΙΟΓβ preferably Release,] ow Osmolality Media > 5 X RclcaSC\\-a[ Physiologic Osmolality Media), even ΠΙΟΓβ preferably RelcaSC] ovv_()smolality Media 10 x ReleaseNear-Physioiogic Osmolality Media) then the test is positive for an osmotic mediated 20 release. “Osmotically active agent” means a substance having solubility in an aqueous solvent. The osmotically active agent(s) may be present in the synthetic nanocarriers in varying amounts. In embodiments, the osmotically active agent is present in the synthetic nanocarriers in an amount of about 2, or 3, or 4, or 5, or 6, or 7, or 8 weight percent, based 25 on the total theoretical weight of the synthetic nanocarriers. The osmotically active agent may comprise more than one molecular entity, including specifically associated soluble materials such as counter-ions. In embodiments, the osmotically active agent comprises an isolated nucleic acid, a polymer, an isolated peptide, an isolated saccharide, macrocycle, or ions, cofactors, coenzymes, ligands, hydrophobically-paired agents, or hydrogen-bond 30 donors or acceptors of any of the above, that are specifically, but non-covalently, associated with any of the foregoing. Osmotically active agents may have a variety of functions in the inventive synthetic nanocarriers. Accordingly osmotically active agents may comprise 19 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 antigens, adjuvants, or substances with other immunostimulatory or immunomodulatory functions. The osmotic contribution of a osmotically-active agent to an aqueous solution can be measured by any of several accepted technologies, not limited to but including, vapor pressure depression, freezing point depression, or membrane osmometers. Specific 5 types of osmometers conventionally available include the Wescor Vapro II vapor pressure osmometer model series, Advanced Instruments 3250 freezing point osmometer model series, and the UIC model 231 membrane osmometer. “pH triggered osmotic mediated release barrier-free synthetic nanocarriers” means osmotic mediated release barrier-free synthetic nanocarriers that release significantly greater 10 amounts of the osmotically-active agent within 1 hour of introduction into an isotonic medium of pH 4.5, or of pH 10.5, than is released into an isotonic medium of pH 7.4. The release is said to be pH triggered if it satisfies the following in vitro test:
Reconstitute or dilute the dosage form to be tested into near neutral-pH aqueous media (e.g., pH 7.4) at 25°C yielding a composition with osmolality between 270-15 330 mOsm/kg, referred to as the Near-Physiologic Osmolality and Near-Neutral pH
Media and measure concentration of the osmotically-active agent upon dilution and after 2 hours of gentle agitation at 37°C. Calculate the total amount of osmotically active agent released over 2 hours, and define the net amount released per 2 hours as the Near-Physiologic Osmolality and Near-Neutral pH Release Rate. Next, repeat 20 the same process in pH 4.5 (or into pH 10.5) aqueous media with osmolality between 270-330 mOsm/kg, referred to as the Acidic (or Basic) Near-Physiologic Osmolality Media. Calculate the total amount of osmotically active agent released over 2 hours, and define the net amount released per 2 hours as the Acidic (or Basic) Near-Physiologic Osmolality Release Rate. If the release rate (e.g., the total 25 osmotically active agent released into solution over 2 hours) is significantly greater in the Acidic (or Basic) Near-Physiologic Osmolality Media than in the Near-Physiologic Osmolality and Near-Neutral pH Media (preferably ReleaseAddic (or Basic) Media1.2 X ReleaSe\ear_\eLnra| Media- more preferably Release Acidic (or Basic) Media ^ 1.5 X Releasexear-Xcutral Media, even more preferably Release Acidic (or Basic) Media 3x 30 Releasexear-Neutrai Media) then the test is positive for a pH triggered osmotic mediated release. 20 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 “Pharmaceutically acceptable excipient” means a pharmacologically inactive material used together with the recited synthetic nanocarriers to formulate the inventive compositions. Pharmaceutically acceptable excipients comprise a variety of materials known in the art, including but not limited to saccharides (such as glucose, lactose, and the 5 like), preservatives such as antimicrobial agents, reconstitution aids, colorants, saline (such as phosphate buffered saline), and buffers. “Polymer” means a synthetic compound comprising large molecules made up of a covalently linked series of repeated simple (co)monomers. In embodiments, polymer comprises osmotically active: dendrimers, polylactic acids, polyglycolic acids, poly lactic -10 co-glycolic acids, polycaprolactams, polyethylene glycols, polyacrylates, polymethacrylates, and co-polymers and/or combinations of any of the above. “Release” or “Release Rate” means the rate that an entrapped substance transfers from a synthetic nanocarrier into local environment, such as a surrounding release media. First, the synthetic nanocarrier is prepared for the release testing by placing into the 15 appropriate release media. This is generally done by exchanging a buffer after centrifugation to pellet the synthetic nanocarrier and reconstitution of the synthetic nanocarriers under a mild condition. The assay is started by placing the sample at 37°C in an appropriate temperature-controlled apparatus. A sample is removed at various time points. 20 The synthetic nanocarriers are separated from the release media by centrifugation to pellet the synthetic nanocarriers. The release media is assayed for the substance that has been released from the synthetic nanocarriers. The substance is measured using HPLC to determine the content and quality of the substance. The pellet containing the remaining entrapped substance is dissolved in solvents or hydrolyzed by base to free the entrapped 25 substance from the synthetic nanocarriers. The pellet-contained substance is then also measured by HPLC after dissolution or destruction of the pellet to determine the content and quality of the substance that has not been released at a given time point.
The mass balance is closed between substance that has been released into the release media and what remains in the synthetic nanocarriers. Data are presented as the fraction 30 released or as the net release presented as micrograms released over time. “Subject” means animals, including warm blooded mammals such as humans and primates; avians; domestic household or farm animals such as cats, dogs, sheep, goats, 21 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 cattle, horses and pigs; laboratory animals such as mice, rats and guinea pigs; fish; reptiles; zoo and wild animals; and the like. “Synthetic nanocarrier(s)” means a discrete object that is not found in nature, and that possesses at least one dimension that is less than or equal to 5 microns in size. 5 Albumin nanoparticles are generally included as synthetic nanocarriers, however in certain embodiments the synthetic nanocarriers do not comprise albumin nanoparticles. In embodiments, inventive synthetic nanocarriers do not comprise chitosan. A synthetic nanocarrier can be, but is not limited to, one or a plurality of lipid-based nanoparticles, polymeric nanoparticles, dendrimers, virus-like particles, peptide or protein-10 based particles (such as albumin nanoparticles), ceramic-based nanoparticles (e.g. semi-porous silicon nanoparticles), hydrogel nanoparticles, polysaccharide-based nanoparticles, and/or nanoparticles that are developed using a combination of nanomaterials such as lipid-polymer nanoparticles. Synthetic nanocarriers may be a variety of different shapes, including but not limited to spheroidal, cuboidal, pyramidal, oblong, cylindrical, toroidal, 15 and the like. Synthetic nanocarriers according to the invention comprise one or more surfaces. Exemplary synthetic nanocarriers that can be adapted for use in the practice of the present invention comprise: (1) the biodegradable nanoparticles disclosed in US Patent 5,543,158 to Gref et al., (2) the polymeric nanoparticles of Published US Patent Application 20060002852 to Saltzman et al., (3) the lithographically constructed nanoparticles of 20 Published US Patent Application 20090028910 to DeSimone et al., (4) the disclosure of WO 2009/051837 to von Andrian et al., (5) the protein nanoparticles disclosed in Published US Patent Application 20090226525 to de los Rios et al., (6) the vims-like particles disclosed in published US Patent Application 20060222652 to Sebbel et al., (7) the nucleic acid coupled vims-like particles disclosed in published US Patent Application 20060251677 25 to Bachmann et al., (8) the vims-like particles disclosed in W02010047839A1 or W02009106999A2, or (9) the nanoprecipitated nanoparticles disclosed in P. Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Vims-like Particles” Nanomedicine. 5(6):843-853 (2010). In embodiments, synthetic nanocarriers may possess an aspect ratio greater than 1:1, 1:1.2, 1:1.5, 1:2, 1:3, 30 1:5, 1:7, or greater than 1:10.
Synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise 22 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 a surface with hydroxyl groups that activate complement or alternatively comprise a surface that consists essentially of moieties that are not hydroxyl groups that activate complement. In a preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 5 100 nm, do not comprise a surface that substantially activates complement or alternatively comprise a surface that consists essentially of moieties that do not substantially activate complement. In a more preferred embodiment, synthetic nanocarriers according to the invention that have a minimum dimension of equal to or less than about 100 nm, preferably equal to or less than 100 nm, do not comprise a surface that activates complement or 10 alternatively comprise a surface that consists essentially of moieties that do not activate complement. In embodiments, synthetic nanocarriers exclude virus-like particles. In embodiments, when synthetic nanocarriers comprise virus-like particles, the virus-like particles comprise non-natural adjuvant (meaning that the VLPs comprise an adjuvant other than naturally occurring RNA generated during the production of the VLPs). 15 “T cell antigen” means any antigen that is recognized by and triggers an immune response in a T cell (e.g., an antigen that is specifically recognized by a T cell receptor on a T cell or an NKT cell via presentation of the antigen or portion thereof bound to a Class I or Class II major histocompatability complex molecule (MHC), or bound to a CD1 complex). In some embodiments, an antigen that is a T cell antigen is also a B cell antigen. In other 20 embodiments, the T cell antigen is not also a B cell antigen. T cell antigens generally are proteins or peptides. T cell antigens may be an antigen that stimulates a CD8+ T cell response, a CD4+ T cell response, or both. The nanocarriers, therefore, in some embodiments can effectively stimulate both types of responses.
In some embodiments the T cell antigen is a T helper cell antigen (i.e. one that can 25 generate an enhanced response to a B cell antigen, preferably an unrelated B cell antigen, through stimulation of T cell help). In embodiments, a T helper cell antigen may comprise one or more peptides obtained or derived from tetanus toxoid, Epstein-Barr virus, influenza virus, respiratory syncytial virus, measles virus, mumps virus, rubella virus, cytomegalovirus, adenovirus, diphtheria toxoid, or a PADRE peptide (known from the work 30 of Sette et al. US Patent 7,202,351). In other embodiments, a T helper cell antigen may comprise one or more lipids, or glycolipids, including but not limited to: a-galactosylceramide (a-GalCer), α-linked glycosphingolipids (from Sphingomonas spp.), 23 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 galactosyl diacylglycerols (from Borrelia burgdorferi), lypophosphoglycan (from Leishmania donovani), and phosphatidylinositol tetramannoside (PIM4) (from Mycobacterium leprae). For additional lipids and/or glycolipids useful as a T helper cell antigen, see V. Cerundolo et al., “Harnessing invariant NKT cells in vaccination strategies.” 5 Nature Rev Immun, 9:28-38 (2009). In embodiments, CD4+ T-cell antigens may be derivatives of a CD4+ T-cell antigen that is obtained from a source, such as a natural source. In such embodiments, CD4+ T-cell antigen sequences, such as those peptides that bind to MHC II, may have at least 70%, 80%, 90%, or 95% identity to the antigen obtained from the source. In embodiments, the T cell antigen, preferably a T helper cell antigen, may 10 be coupled to, or uncoupled from, a synthetic nanocarrier. “Vaccine” means a composition of matter that improves the immune response to a particular pathogen or disease. A vaccine typically contains factors (such as antigens, adjuvants, and the like) that stimulate a subject's immune system to recognize a specific antigen as foreign and eliminate it from the subject’s body. A vaccine also establishes an 15 immunologic ‘memory’ so the antigen will be quickly recognized and responded to if a person is re-challenged. Vaccines can be prophylactic (for example to prevent future infection by any pathogen), or therapeutic (for example a vaccine against a tumor specific antigen for the treatment of cancer). In embodiments, a vaccine may comprise dosage forms according to the invention. 20 “Vehicle” means a material of little or no therapeutic value used to convey synthetic nanocarriers for administration. In a preferred embodiment, vehicles according to the invention comprise those vehicles having an osmolality of 200-500 mOsm/kg. C. INVENTIVE COMPOSITIONS 25 A wide variety of synthetic nanocarriers can be used according to the invention. In some embodiments, synthetic nanocarriers are spheres or spheroids. In some embodiments, synthetic nanocarriers are flat or plate-shaped. In some embodiments, synthetic nanocarriers are cubes or cubic. In some embodiments, synthetic nanocarriers are ovals or ellipses. In 30 some embodiments, synthetic nanocarriers are cylinders, cones, or pyramids.
In some embodiments, it is desirable to use a population of synthetic nanocarriers that is relatively uniform in terms of size, shape, and/or composition so that each synthetic 24 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 nanocarrier has similar properties. For example, at least 80%, at least 90%, or at least 95% of the synthetic nanocarriers, based on the total number of synthetic nanocarriers, may have a minimum dimension or maximum dimension that falls within 5%, 10%, or 20% of the average diameter or average dimension of the synthetic nanocarriers. In some 5 embodiments, a population of synthetic nanocarriers may be heterogeneous with respect to size, shape, and/or composition.
Synthetic nanocarriers can be solid or hollow and can comprise one or more layers -so long as the layers do not act as a release rate-controlling barrier, located on or within a surface of the synthetic nanocarriers, that controls the release rate of the encapsulated 10 osmotically active agent from the synthetic nanocarriers into an environment surrounding the nanocarriers. In some embodiments, each layer has a unique composition and unique properties relative to the other layer(s). To give but one example, synthetic nanocarriers may have a core/shell structure, wherein the core is one layer (e.g. a polymeric core) and the shell is a second layer (e.g. a lipid bilayer or monolayer). Synthetic nanocarriers may 15 comprise a plurality of different layers.
In some embodiments, synthetic nanocarriers may optionally comprise one or more lipids, so long as the lipids do not function as a release rate-controlling barrier, located on or within a surface of the synthetic nanocarriers, that controls the release rate of the encapsulated osmotically active agent from the synthetic nanocarriers into an environment 20 surrounding the nanocarriers. In some embodiments, a synthetic nanocarrier may comprise a liposome. In some embodiments, a synthetic nanocarrier may comprise a lipid bilayer. In some embodiments, a synthetic nanocarrier may comprise a lipid monolayer. In some embodiments, a synthetic nanocarrier may comprise a micelle. In some embodiments, a synthetic nanocarrier may comprise a core comprising a polymeric matrix surrounded by a 25 lipid layer (e.g., lipid bilayer, lipid monolayer, etc.). In some embodiments, a synthetic nanocarrier may comprise a non-polymeric core (e.g., viral particle, proteins, nucleic acids, carbohydrates, etc.) surrounded by a lipid layer (e.g., lipid bilayer, lipid monolayer, etc.).
In some embodiments, synthetic nanocarriers can comprise one or more polymers.
In some embodiments, such a polymer can be surrounded by a coating layer (e.g., liposome, 30 lipid monolayer, micelle, etc.) so long as the coating layer does not function as a release rate-controlling barrier, located on or within a surface of the synthetic nanocarriers, that controls the release rate of the encapsulated osmotically active agent from the synthetic 25 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 nanocarriers into an environment surrounding the nanocarriers. In some embodiments, various elements of the synthetic nanocarriers can be coupled with the polymer.
In some embodiments, an element, such as an immunofeature surface, targeting moiety, and/or oligonucleotide can be covalently associated with a polymeric matrix. In 5 some embodiments, covalent association is mediated by a linker. In some embodiments, an element, such as an immunofeature surface, targeting moiety, and/or oligonucleotide can be noncovalently associated with a polymeric matrix. For example, in some embodiments, element, such as an immunofeature surface, targeting moiety, and/or oligonucleotide can be encapsulated within, surrounded by, and/or dispersed throughout a polymeric matrix. 10 Alternatively or additionally, an element, such as an immunofeature surface, targeting moiety, and/or nucleotide can be associated with a polymeric matrix by hydrophobic interactions, charge interactions, van der Waals forces, etc. A wide variety of polymers and methods for forming polymeric matrices therefrom are known conventionally. In general, a polymeric matrix comprises one or more 15 polymers. Polymers may be natural or unnatural (synthetic) polymers. Polymers may be homopolymers or copolymers comprising two or more monomers. In terms of sequence, copolymers may be random, block, or comprise a combination of random and block sequences. Typically, polymers in accordance with the present invention are organic polymers. 20 Examples of polymers suitable for use in the present invention include, but are not limited to polyethylenes, polycarbonates (e.g. poly(l,3-dioxan-2one)), polyanhydrides (e.g. poly(sebacic anhydride)), polypropylfumerates, polyamides (e.g. polycaprolactam), polyacetals, polyethers, polyesters (e.g., polylactide, polyglycolide, polylactide-co-glycolide, polycaprolactone, polyhydroxyacid (e.g. poly(P-hydroxyalkanoate))), 25 poly(orthoesters), polycyanoacrylates, polyvinyl alcohols, polyurethanes. polyphosphazenes, polyacrylates, polymethacrylates, polyureas, polystyrenes, and polyamines, polylysine, polylysine-PEG copolymers, and poly(ethyleneimine), poly(ethylene imine)-PEG copolymers.
In some embodiments, polymers in accordance with the present invention include 30 polymers which have been approved for use in humans by the U.S. Food and Drug
Administration (FDA) under 21 C.F.R. § 177.2600, including but not limited to polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, 26 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 poly(l,3-dioxan-2one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates.
In some embodiments, polymers can be hydrophilic. For example, polymers may 5 comprise anionic groups (e.g., phosphate group, sulphate group, carboxylate group); cationic groups (e.g., quaternary amine group); or polar groups (e.g., hydroxyl group, thiol group, amine group). In some embodiments, a synthetic nanocarrier comprising a hydrophilic polymeric matrix generates a hydrophilic environment within the synthetic nanocarrier. In some embodiments, polymers can be hydrophobic. In some embodiments, a 10 synthetic nanocarrier comprising a hydrophobic polymeric matrix generates a hydrophobic environment within the synthetic nanocarrier. Selection of the hydrophilicity or hydrophobicity of the polymer may have an impact on the nature of materials that are incorporated (e.g. coupled) within the synthetic nanocarrier.
In some embodiments, polymers may be modified with one or more moieties and/or 15 functional groups. A variety of moieties or functional groups can be used in accordance with the present invention. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides (Papisov, 2001, ACS Symposium Series, 786:301). Certain embodiments may be made using the general teachings of US Patent No. 5543158 to Gref et 20 al., or WO publication W02009/051837 by Von Andrian et al.
In some embodiments, polymers may be modified with a lipid or fatty acid group. In some embodiments, a fatty acid group may be one or more of butyric, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, arachidic, behenic, or lignoceric acid. In some embodiments, a fatty acid group may be one or more of palmitoleic, oleic, vaccenic, 25 linoleic, alpha-linoleic, gamma-linoleic, arachidonic, gadoleic, arachidonic, eicosapentaenoic, docosahexaenoic, or erucic acid.
In some embodiments, polymers may be polyesters, including copolymers comprising lactic acid and glycolic acid units, such as poly(lactic acid-co-glycolic acid) and poly(lactide-co-glycolide), collectively referred to herein as “PLGA”; and homopolymers 30 comprising glycolic acid units, referred to herein as “PGA,” and lactic acid units, such as poly-L-lactic acid, poly-D-lactic acid, poly-D,L-lactic acid, poly-L-lactide, poly-D-lactide, and poly-D,L-lactide, collectively referred to herein as “PLA.” In some embodiments, 27 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 exemplary polyesters include, for example, polyhydroxyacids; PEG copolymers and copolymers of lactide and glycolide (e.g., PLA-PEG copolymers, PGA-PEG copolymers, PLGA-PEG copolymers, and derivatives thereof. In some embodiments, polyesters include, for example, poly(caprolactone), poly(caprolactone)-PEG copolymers, poly(L-lactide-co-L-5 lysine), poly(serine ester), poly(4-hydroxy-L-proline ester), poly[a-(4-aminobutyl)-L-glycolic acid], and derivatives thereof.
In some embodiments, a polymer may be PLGA. PLGA is a biocompatible and biodegradable co-polymer of lactic acid and glycolic acid, and various forms of PLGA are characterized by the ratio of lactic acidrglycolic acid. Lactic acid can be L-lactic acid, D-10 lactic acid, or D,L-lactic acid. The degradation rate of PLGA can be adjusted by altering the lactic acidrglycolic acid ratio. In some embodiments, PLGA to be used in accordance with the present invention is characterized by a lactic acidrglycolic acid ratio of approximately 85:15, approximately 75:25, approximately 60:40, approximately 50:50, approximately 40:60, approximately 25:75, or approximately 15:85. 15 In some embodiments, polymers may be one or more acrylic polymers. In certain embodiments, acrylic polymers include, for example, acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl methacrylates, cyanoethyl methacrylate, aminoalkyl methacrylate copolymer, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), poly(methacrylic 20 acid anhydride), methyl methacrylate, polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, glycidyl methacrylate copolymers, polycyanoacrylates, and combinations comprising one or more of the foregoing polymers. The acrylic polymer may comprise fully-polymerized copolymers of acrylic and methacrylic acid esters with a low content of quaternary ammonium groups. 25 The properties of these and other polymers and methods for preparing them are well known in the art (see, for example, U.S. Patents 6,123,727; 5,804,178; 5,770,417; 5,736,372; 5,716,404; 6,095,148; 5,837,752; 5,902,599; 5,696,175; 5,514,378; 5,512,600; 5,399,665; 5,019,379; 5,010,167; 4,806,621; 4,638,045; and 4,946,929; Wang et al., 2001, J. Am. Chem. Soc., 123:9480; Lim et al., 2001, J. Am. Chem. Soc., 123:2460; Langer, 30 2000, Acc. Chem. Res., 33:94; Langer, 1999, J. Control. Release, 62:7; and Uhrich et al., 1999, Chem. Rev., 99:3181). More generally, a variety of methods for synthesizing certain suitable polymers are described in Concise Encyclopedia of Polymer Science and Polymeric 28 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
Amines and Ammonium Salts, Ed. by Goethals, Pergamon Press, 1980; Principles of Polymerization by Odian, John Wiley & Sons, Fourth Edition, 2004; Contemporary Polymer Chemistry by Allcock et al., Prentice-Hall, 1981; Deming et al., 1997, Nature, 390:386; and in U.S. Patents 6,506,577, 6,632,922, 6,686,446, and 6,818,732. 5 In some embodiments, polymers can be linear or branched polymers. In some embodiments, polymers can be dendrimers. In some embodiments, polymers can be substantially cross-linked to one another. In some embodiments, polymers can be substantially free of cross-links. In some embodiments, polymers can be used in accordance with the present invention without undergoing a cross-linking step. It is further to be 10 understood that inventive synthetic nanocarriers may comprise block copolymers, graft copolymers, blends, mixtures, and/or adducts of any of the foregoing and other polymers. Those skilled in the art will recognize that the polymers listed herein represent an exemplary, not comprehensive, list of polymers that can be of use in accordance with the present invention. 15 In some embodiments, synthetic nanocarriers may optionally comprise one or more amphiphilic entities. In some embodiments, an amphiphilic entity can promote the production of synthetic nanocarriers with increased stability, improved uniformity, or increased viscosity. Many amphiphilic entities known in the art are suitable for use in making synthetic nanocarriers in accordance with the present invention. Such amphiphilic 20 entities include, but are not limited to, phosphoglycerides; phosphatidylcholines; dipalmitoyl phosphatidylcholine (DPPC); dioleylphosphatidyl ethanolamine (DOPE); dioleyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohols such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl 25 ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acids; fatty acid monoglycerides; fatty acid diglycerides; fatty acid amides; sorbitan trioleate (Span®85) glycocholate; sorbitan monolaurate (Span®20); polysorbate 20 (Tween®20); polysorbate 60 (Tween®60); polysorbate 65 (Tween®65); polysorbate 80 (Tween®80); polysorbate 85 (Tween®85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid 30 ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol;sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebrosides; dicetylphosphate; dipalmitoylphosphatidylglycerol; 29 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl sterate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipids; synthetic and/or natural detergents having high surfactant properties; deoxycholates; 5 cyclodextrins; chaotropic salts; ion pairing agents; and combinations thereof. An amphiphilic entity component may be a mixture of different amphiphilic entities. Those skilled in the art will recognize that this is an exemplary, not comprehensive, list of substances with surfactant activity. Any amphiphilic entity may be used in the production of synthetic nanocarriers to be used in accordance with the present invention. 10 In some embodiments, synthetic nanocarriers may optionally comprise one or more carbohydrates. Carbohydrates may be natural or synthetic. A carbohydrate may be a derivatized natural carbohydrate. In certain embodiments, a carbohydrate comprises monosaccharide or disaccharide, including but not limited to glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, 15 glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid. In certain embodiments, a carbohydrate is a polysaccharide, including but not limited to pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, Ν,Ο-carboxylmethylchitosan, 20 algin and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan. In embodiments, the inventive synthetic nanocarriers do not comprise (or specifically exclude) carbohydrates, such as a polysaccharide. In certain embodiments, the carbohydrate may comprise a carbohydrate derivative such as a sugar alcohol, including but not limited to mannitol, sorbitol, xylitol, erythritol, maltitol, 25 and lactitol.
Compositions according to the invention comprise inventive synthetic nanocarriers in combination with pharmaceutically acceptable excipients, such as preservatives, buffers, saline, or phosphate buffered saline. The compositions may be made using conventional pharmaceutical manufacturing and compounding techniques to arrive at useful dosage 30 forms. In an embodiment, inventive synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative. 30 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
In embodiments, when preparing synthetic nanocarriers as carriers for antigens and/or adjuvants for use in vaccines, methods for coupling the antigens and/or adjuvants to the synthetic nanocarriers may be useful. If the adjuvant is a small molecule it may be of advantage to attach the antigens and/or adjuvants to polymers prior to the assembly of the 5 synthetic nanocarriers. In embodiments, it may also be an advantage to prepare the synthetic nanocarriers with surface groups that are used to couple the antigens and/or adjuvants to the synthetic nanocarriers through the use of these surface groups rather than attaching the antigens and/or adjuvants to polymers and then using the polymer conjugates in the construction of synthetic nanocarriers. 10 In certain embodiments, the coupling can be a covalent linker. In embodiments, antigens and/or adjuvants can be covalently coupled to an external synthetic nanocarrier surface via a 1,2,3-triazole linker formed by the 1,3-dipolar cycloaddition reaction of azido groups on the surface of the nanocarrier with antigen and/or adjuvant containing an alkyne group or by the 1,3-dipolar cycloaddition reaction of alkynes on the surface of the 15 nanocarrier with antigens or adjuvants containing an azido group. Such cycloaddition reactions are preferably performed in the presence of a Cu(I) catalyst along with a suitable Cu(I)-ligand and a reducing agent to reduce Cu(II) compound to catalytic active Cu(I) compound. This Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) can also be referred as the click reaction. Additionally, the covalent coupling may comprise a covalent linker 20 that comprises an amide linker, a disulfide linker, a thioether linker, a hydrazone linker, a hydrazide linker, an imine or oxime linker, an urea or thiourea linker, an amidine linker, an amine linker, and a sulfonamide linker.
Elements of the inventive synthetic nanocarriers (such as moieties of which an immunofeature surface is comprised, targeting moieties, polymeric matrices, antigens and 25 the like) may be coupled to the overall synthetic nanocarrier, e.g., by one or more covalent bonds, or may be coupled by means of one or more linkers. Additional methods of functionalizing synthetic nanocarriers may be adapted from Published US Patent Application 2006/0002852 to Saltzman et al., Published US Patent Application 2009/0028910 to DeSimone et al., or Published International Patent Application 30 WO/2008/127532 Al to Murthy et al.
Alternatively or additionally, synthetic nanocarriers can be coupled to immunofeature surfaces, targeting moieties, adjuvants, various antigens, and/or 31 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 other elements directly or indirectly via non-covalent interactions. In non-covalent embodiments, the non-covalent coupling is mediated by non-covalent interactions including but not limited to charge interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, hydrophobic interactions, TT stacking interactions, 5 hydrogen bonding interactions, van der Waals interactions, magnetic interactions, electrostatic interactions, dipole-dipole interactions, and/or combinations thereof. Such couplings may be arranged to be on an external surface or an internal surface of an inventive synthetic nanocarrier. In embodiments, encapsulation and/or absorption is a form of coupling. 10 For detailed descriptions of additional available conjugation methods, see
Hermanson G T “Bioconjugate Techniques”, 2nd Edition Published by Academic Press, Inc., 2008.
D. METHODS OF MAKING AND USING THE INVENTIVE COMPOSITIONS 15 AND RELATED METHODS
In an embodiment, a novel factor in creating and maintaining the inventive synthetic nanocarriers is the use of osmotic balancing at near-physiologic osmolality during processing and storage. In an embodiment, during the assembly and dosage preparation of inventive synthetic nanocarriers that comprise osmotically active agent(s), osmolality plays 20 an important role.
Balance of the osmolality (e.g., between inner and outer aqueous phases) can be important for efficient loading during preparation of inventive synthetic nanocarrier formulations. The inventors have recognized that optimal efficacy of an inventive nanocarrier preparation as a means to administer osmotically active agents to a biological 25 system implies an optimum preparative osmolality corresponding approximately to that of the physiologic target. In an embodiment, maintaining osmotic balance at a near-physiological level throughout processing and formulation provides for optimized inventive synthetic nanocarriers with respect to encapsulation efficiency, loading stability during storage and dosing, and effective delivery. 30 In embodiments according to the invention, osmotic mediated release barrier-free nanocarriers are formed in environments having an osmolality ranging from 200-500 32 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 mOsm/kg. Environments having an osmolality in this range mimic the local osmotic environment found in subjects to whom the inventive dosage forms might be administered.
Environments according to the invention may be prepared at a specified osmolality using a variety of techniques. For instance, the concentration of ions having osmotic 5 activity may be titrated up or down to achieve the desired osmolality. Materials that can be used to increase or decrease environmental osmolality comprise salts and buffering agents (such as NaCl, CaCl2, or NaPO,*), simple or complex carbohydrates (such as sucrose, dextrose, dextran, or sodium carboxymethyl cellulose), polyols (such as sorbitol, glycerol, or polyvinyl alcohol), pH adjustment agents (such as HC1, NaOH, or acetic acid), amino 10 acids and peptides (such as glycine, histidine, and ), chelating or antioxidant agents (such as EDTA, ascorbic acid), vitamins, dissolved gasses, water-soluble polymers (e.g., polyvinylpyrrolidone, poloxamer, or polyethyleneglycol), and preservative and antimicrobials (such as benzoic acid). The agents that contribute to the osmolality of processing media or environments may have additional functional roles in addition to 15 osmolality adjustment. To reduce osmolality, dilution is the traditional method, for example diluting an environment with water or with another aqueous medium having lower osmolality. Furthermore, lower osmolality could be induced in the environment of the nanocarrier (or its in-process form) by removing osmotic agents from the nanocarrier media, for example by precipitation or by liquid-liquid extraction. For example, in an embodiment, 20 a condensing agent such as chitosan could be added to the aqueous media which may cause soluble ions to precipitate. Chelating agents and resins may also be introduced into the environment to reduce the net solute concentration. An example of liquid-liquid extraction would include the contact of an organic phase (such as dichloromethane) with the aqueous environment such that a water-soluble agent will partition, at least in part, into the 25 dichloromethane phase (e.g., benzoic acid). The osmolality of an aqueous solution can be measured by any of several accepted technologies, not limited to but including, vapor pressure depression, freezing point depression, or membrane osmometers. As noted elsewhere herein, useful types of osmometers include the Wescor Vapro II vapor pressure osmometer model series, Advanced Instruments 3250 freezing point osmometer model 30 series, and the UIC model 231 membrane osmometer.
In embodiments, once the osmotic mediated release barrier-free synthetic nanocarriers are formed, they may be maintained in an environment that has an osmolality 33 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 ranging from 200-500 mOsm/kg. This may help to preserve the integrity of the synthetic nanocarriers, and also reduce or prevent undesirable or premature release of the osmotically active agent during manufacture of the osmotic mediated release barrier-free synthetic nanocarriers. In embodiments, the specific environment may be changed, using methods 5 like dialysis or centrifugation followed by resuspension. In other embodiments, the environment in which the osmotic mediated release barrier-free synthetic nanocarriers are formed, and the environment in which the osmotic mediated release barrier-free synthetic nanocarriers are maintained, are the same. Situations in which the environment is changed or kept the same may be driven by the nature of the manufacturing processes involved, the 10 type of synthetic nanocarriers being manufactured, and the nature of the osmotically active agent(s), among other factors. The osmolality of the environment can be monitored using various measurement techniques as described elsewhere herein, and osmolality can be maintained using titration of various reagents again as described elsewhere herein.
In embodiments, the formed osmotic mediated release barrier-free synthetic 15 nanocarriers may be processed in an environment having an osmolality ranging from 200-500 mOsm/kg. In embodiments, processing can comprise a number of different unit operations that may comprise: washing the synthetic nanocarriers, centrifuging the synthetic nanocarriers, filtering the synthetic nanocarriers, concentrating or diluting the synthetic nanocarriers, freezing the synthetic nanocarriers, drying the synthetic nanocarriers, 20 combining the synthetic nanocarriers with other synthetic nanocarriers or with additive agents or excipients, adjusting the pH or buffer environment of the synthetic nanocarriers, entrapping the synthetic nanocarriers in a gel or high-viscosity medium, resuspending the synthetic nanocarriers, surface modifying the synthetic nanocarriers covalently or by physical processes such as coating or annealing, impregnating or doping the synthetic 25 nanocarriers with active agents or excipients, sterilizing the synthetic nanocarriers, reconstituting the synthetic nanocarriers for administration, or combinations of any of the above. Additionally, in embodiments the formed osmotic mediated release barrier-free synthetic nanocarriers may be stored in an environment having an osmolality ranging from 200-500 mOsm/kg. Again, processing in such an environment may help to preserve the 30 integrity of the synthetic nanocarriers, and also reduce or prevent undesirable or premature release of the osmotically active agent during manufacture of the osmotic mediated release barrier-free synthetic nanocarriers. The specific materials making up the processing or 34 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 storage environments may be changed or kept the same, so long as the environment is maintained at an osmolality ranging from 200-500 mOsm/kg.
In embodiments, the formed osmotic mediated release barrier-free synthetic nanocarriers may be formulated into a dosage form that maintains the formed osmotic 5 mediated release barrier-free synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg. In embodiments, the environment may comprise a vehicle that is formulated to have osmolality ranging from 200-500 mOsm/kg. The vehicle’s molality may be established using techniques and materials disclosed elsewhere herein for creating and/or maintaining an environmental osmolality, with the exception that the 10 materials and techniques chosen must be suitable for the type of dosage form in question. For instance, materials used to increase the osmolality of the vehicle in an injectable dosage form should be suitable for use in parenteral dosage forms. Suspension, gel, or frozen suspension dosage forms may be prepared to an appropriate osmolality with the inclusion of osmolality adjustment agents. Examples of these include, but are not limited to, water-15 soluble buffers, salts, carbohydrates, polyols, amino acids, ions, and co-solvents that contribute to the osmotic pressure of the dosage form, along with other such agents noted elsewhere herein. If the dosage form is to be lyophilized, conventional lyophilization equipment run at conventional settings can be used in the practice of the present invention.
In embodiments, dosage forms that are to be administered to subjects comprise 20 osmotic mediated release barrier-free synthetic nanocarriers that are processed only in environments having an osmolality ranging from 200-500 mOsm/kg, thus preventing undesirable release (e.g. premature or in an inappropriate environment) of osmotically active agent. Such processing comprises: washing the synthetic nanocarriers, centrifuging the synthetic nanocarriers, filtering the synthetic nanocarriers, concentrating or diluting the 25 synthetic nanocarriers, freezing the synthetic nanocarriers, drying the synthetic nanocarriers, combining the synthetic nanocarriers with other synthetic nanocarriers or with additive agents or excipients, adjusting the pH or buffer environment of the synthetic nanocarriers, entrapping the synthetic nanocarriers in a gel or high-viscosity medium, resuspending the synthetic nanocarriers, surface modifying the synthetic nanocarriers covalently or by 30 physical processes such as coating or annealing, impregnating or doping the synthetic nanocarriers with active agents or excipients, sterilizing the synthetic nanocarriers, 35 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 reconstituting the synthetic nanocarriers for administration, or combinations of any of the above.
Synthetic nanocarriers may be prepared using a wide variety of methods known in the art. For example, synthetic nanocarriers can be formed by methods as 5 nanoprecipitation, flow focusing using fluidic channels, spray drying, single and double emulsion solvent evaporation, solvent extraction, phase separation, milling, microemulsion procedures, microfabrication, nanofabrication, sacrificial layers, simple and complex coacervation, and other methods well known to those of ordinary skill in the art. Alternatively or additionally, aqueous and organic solvent syntheses for monodisperse 10 semiconductor, conductive, magnetic, organic, and other nanomaterials have been described (Pellegrino et al., 2005, Small, 1:48; Murray et al., 2000, Ann. Rev. Mat. Sci., 30:545; and Trindade et al., 2001, Chem. Mat., 13:3843). Additional methods have been described in the literature (see, e.g., Doubrow, Ed., “Microcapsules and Nanoparticles in Medicine and Pharmacy,” CRC Press, Boca Raton, 1992; Mathiowitz et al., 1987, J. Control. Release, 15 5:13; Mathiowitz et al., 1987, Reactive Polymers, 6:275; and Mathiowitz et al., 1988, J.
Appl. Polymer Sci., 35:755; US Patents 5578325 and 6007845; P. Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles” Nanomedicine. 5(6):843-853 (2010)).
Various materials may be encapsulated into synthetic nanocarriers as desirable using 20 a variety of methods including but not limited to C. Astete et al., “Synthesis and characterization of PLGA nanoparticles” J. Biomater. Sci. Polymer Edn, Vol. 17, No. 3, pp. 247-289 (2006); K. Avgoustakis “Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery” Current Drug Delivery 1:321-333 (2004); C. Reis et al., “Nanoencapsulation I. Methods for 25 preparation of drug-loaded polymeric nanoparticles” Nanomedicine 2:8- 21 (2006); P. Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles” Nanomedicine. 5(6):843-853 (2010). Other methods suitable for encapsulating materials, such as nucleic acids, into synthetic nanocarriers may be used, including without limitation methods disclosed in United States 30 Patent 6,632,671 to Unger October 14, 2003.
In certain embodiments, synthetic nanocarriers are prepared by a nanoprecipitation process or spray drying. Conditions used in preparing synthetic nanocarriers may be altered 36 PCT/U S2012/030314 WO 2012/135010 2017203307 17 May 2017 to yield particles of a desired size or property (e.g., hydrophobicity, hydrophilicity, external morphology, “stickiness,” shape, etc.). The method of preparing the synthetic nanocarriers and the conditions (e.g., solvent, temperature, concentration, air flow rate, etc.) used may depend on the materials to be coupled to the synthetic nanocarriers and/or the composition 5 of the polymer matrix.
If particles prepared by any of the above methods have a size range outside of the desired range, particles can be sized, for example, using a sieve.
In embodiments, the inventive synthetic nanocarriers can be combined with other adjuvants by admixing in the same vehicle or delivery system. Such adjuvants may include, 10 but are not limited to mineral salts, such as alum, alum combined with monphosphoryl lipid (MPL) A of Enterobacteria, such as Escherihia coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri or specifically with MPL® (AS04), MPL A of above-mentioned bacteria separately, saponins, such as QS-21,Quil-A, ISCOMs, ISCOMATRIX™, emulsions such as ML59™, Montanide® ISA 51 and ISA 720, AS02 15 (QS21+squalene+ MPL®), liposomes and liposomal formulations such as AS01, synthesized or specifically prepared microparticles and microcarriers such as bacteria-derived outer barrier vesicles (OMV) of N. gonorrheae, Chlamydia trachomatis and others, or chitosan particles, depot-forming agents, such as Pluronic® block co-polymers, specifically modified or prepared peptides, such as muramyl dipeptide, aminoaikyi 20 ghicosamini.de 4-phosphates, such as RC529, or proteins, such as bacterial toxoids or toxin fragments. The doses of such other adjuvants can be determined using conventional dose ranging studies.
In embodiments, the inventive synthetic nanocarriers can be combined with an antigen different, similar or identical to those coupled to a nanocarrier (with or without 25 adjuvant, utilizing or not utilizing another delivery vehicle) administered separately at a different time-point and/or at a different body location and/or by a different immunization route or with another antigen and/or adjuvant-carrying synthetic nanocarrier administered separately at a different time-point and/or at a different body location and/or by a different immunization route. 30 Various synthetic nanocarriers may be combined to form inventive dosage forms according to the present invention using traditional pharmaceutical mixing methods. These include liquid-liquid mixing in which two or more suspensions, each containing one or 37 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 more subset of nanocarriers, are directly combined or are brought together via one or more vessels containing diluent. As synthetic nanocarriers may also be produced or stored in a powder form, dry powder-powder mixing could be performed as could the re-suspension of two or more powders in a common media. Depending on the properties of the nanocarriers 5 and their interaction potentials, there may be advantages conferred to one or another route of mixing.
In embodiments, dosage forms according to the invention comprise inventive synthetic nanocarriers in combination with pharmaceutically acceptable excipients. The compositions may be made using conventional pharmaceutical manufacturing and 10 compounding techniques to arrive at useful dosage forms. Techniques suitable for use in practicing the present invention may be found in Handbook of Industrial Mixing: Science and Practice, Edited by Edward L. Paul, Victor A. Atiemo-Obeng, and Suzanne M. Kresta, 2004 John Wiley & Sons, Inc.; and Pharmaceutics: The Science of Dosage Form Design. 2nd Ed. Edited by Μ. E. Auten, 2001, Churchill Livingstone. In an embodiment, inventive 15 synthetic nanocarriers are suspended in sterile saline solution for injection together with a preservative. In embodiments, inventive dosage forms can comprise excipients, such as but not limited to, inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate, or citrate) and pH adjustment agents (e.g., hydrochloric acid, sodium or potassium hydroxide, salts of citrate or acetate, amino acids and their salts) antioxidants 20 (e.g., ascorbic acid, alpha-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene9-10 nonyl phenol, sodium desoxycholate), solution and/or cryo/lyo stabilizers (e.g., sucrose, lactose, mannitol, trehalose), antibacterial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsilozone), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity-adjustment 25 agents (e.g., polyvinylpyrrolidone, poloxamer 488, carboxymethylcellulose) and co-solvents (e.g., glycerol, polyethylene glycol, ethanol). In particular embodiments, the dosage forms may also comprise osmotic adjustment agents (e.g., salts or sugars) that are used to modify the osmolality of the dosage form to be within desired ranges (e.g. 200-500 mOsm/kg).
Inventive synthetic nanocarriers, and inventive dosage forms comprising such 30 synthetic nanocarriers, can be used in a wide variety of applications, including delivery of osmotically active agents to desired compartments in a subject. In certain embodiments, the inventive synthetic nanocarriers can be used to deliver osmotically active agents such as 38 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 isolated nucleic acids at much higher loadings than would be achievable conventionally. This characteristic can be valuable, for instance, in increasing adjuvant loadings in the synthetic nanocarriers in embodiments wherein the osmotically active agent comprises an adjuvant. The use of the inventive synthetic nanocarriers provides an additional benefit in 5 providing more control over release rates of the osmotically active agent as compared to conventional techniques (diffusive barriers, condensing agents, etc.) for loading osmotically active agents into nanoparticles, liposomes, etc.
It is to be understood that the compositions of the invention can be made in any suitable manner, and the invention is in no way limited to compositions that can be 10 produced using the methods described herein. Selection of an appropriate method may require attention to the properties of the osmotically active agent, the synthetic nanocarriers, and other elements of the inventive dosage forms.
In some embodiments, inventive synthetic nanocarriers are manufactured under sterile conditions or are terminally sterilized. This can ensure that resulting composition are 15 sterile and non-infectious, thus improving safety when compared to non-sterile compositions. This provides a valuable safety measure, especially when subjects receiving synthetic nanocarriers have immune defects, are suffering from infection, and/or are susceptible to infection. In some embodiments, inventive synthetic nanocarriers may be lyophilized and stored in suspension or as lyophilized powder depending on the formulation 20 strategy for extended periods without losing activity.
The inventive compositions may be administered by a variety of routes of administration, including but not limited to subcutaneous, intramuscular, intradermal, oral, intranasal, transmucosal, sublingual, rectal, ophthalmic, transdermal, transcutaneous or by a combination of these routes. 25 Doses of dosage forms contain varying amounts of synthetic nanocarriers, according to the invention. The amount of synthetic nanocarriers present in the inventive dosage forms can be varied according to the therapeutic benefit to be accomplished, and other such parameters. In embodiments, dose ranging studies can be conducted to establish optimal therapeutic amount of the synthetic nanocarriers to be present in the dosage form. Inventive 30 dosage forms may be administered at a variety of frequencies. In a preferred embodiment, at least one administration of the dosage form is sufficient to generate a pharmacologically relevant response. In more preferred embodiment, at least two administrations, at least 39 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 three administrations, or at least four administrations, of the dosage form are utilized to ensure a pharmacologically relevant response.
The compositions and methods described herein can be used to induce, enhance, suppress, modulate, direct, or redirect an immune response. The compositions and methods 5 described herein can be used in the diagnosis, prophylaxis and/or treatment of conditions such as cancers, infectious diseases, metabolic diseases, degenerative diseases, autoimmune diseases, inflammatory diseases, immunological diseases, or other disorders and/or conditions. The compositions and methods described herein can also be used for the prophylaxis or treatment of an addiction, such as an addiction to nicotine or a narcotic. The 10 compositions and methods described herein can also be used for the prophylaxis and/or treatment of a condition resulting from the exposure to a toxin, hazardous substance, environmental toxin, or other harmful agent.
Also within the scope of the invention are kits comprising the compositions or dosage forms of the invention with or without instructions for use and/or mixing. The kits 15 can further contain at least one additional reagent, such as a reconstitution agent or pharmaceutically acceptable carrier, or one or more additional compositions or dosage forms of the invention. Kits containing the compositions or dosage forms of the invention can be prepared for the therapeutic applications described above. The components of the kits can be packaged either in aqueous medium or in lyophilized form. A kit may comprise 20 a carrier being compartmentalized to receive in close confinement therein one or more container means or series of container means such as test tubes, vials, flasks, bottles, syringes, or the like. A first of said container means or series of container means may contain one or more compositions or dosage forms of the invention. A second container means or series of container means may contain an additional reagent, such as a 25 reconstitution agent or pharmaceutically acceptable carrier.
E. EXAMPLES
The invention will be more readily understood by reference to the following 30 examples, which are included merely for purposes of illustration of certain aspects and embodiments of the present invention and not as limitations. 40 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
Those skilled in the art will appreciate that various adaptations and modifications of the just-described embodiments can be configured without departing from the scope and spirit of the invention. Other suitable techniques and methods known in the art can be applied in numerous specific modalities by one skilled in the art and in light of the 5 description of the present invention described herein.
Therefore, it is to be understood that the invention can be practiced other than as specifically described herein. The above description is intended to be illustrative, and not restrictive. Many other embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be 10 determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
Example 1: Osmolality effect of the outer aqueous phase in a W1/O/W2 emulsion used to produce immunostimulatory oligonucleotide-loaded synthetic nanocarriers. 15 Dosage forms comprising osmotic mediated release barrier-free synthetic nanocarriers comprising an encapsulated osmotically active agent were prepared. In this example, the synthetic nanocarriers comprised PLGA, PLA-PEG-Nic, and PS-1826 CpG. The synthetic nanocarriers were prepared via a double emulsion method wherein the PS-1826 oligonucleotide (the osmotically active agent) was encapsulated in the nanocarriers. 20 Formulation elements:
Wi = 100 mg/mL of PO-1826 oligonucleotide in water, calculated osmolality = 330 mOsm/kg W2 = a. 5% PVA in 100 mM Phosphate buffer pH 8, calculated osmolality = 296 mOsm/kg or 25 b. 5% PVA in endotoxin-free RO-water, calculated osmolality = 3 mOsm/kg or c. 5% PVA in 100 mM phosphate buffer pH 8 with 0.5M NaCl, calculated osmolality = 1300 mOsm/kg
The polyvinyl alcohol (Mw = 11 KD - 31 KD, 87-89% partially hydrolyzed) was
30 purchased from JT Baker. PS-1826 CpG was obtained from Oligos Etc. 9775 SW
Commerce Circle C-6, Wilsonville, OR 97070). PLGA 7525 DLG 7A was purchased from 41 WO 2012/135010 PCT/US2012/030314 2017203307 17 May 2017 5 10 15 20 25 30 from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, AL 35211). PLA-PEG-Nic with approximate molecular weight of 22 kD was synthesized and purified. The above materials were used to prepare the following solutions: 1. PS-1826 CpG in water @ 100 mg/mL 2. PLGA 7525 DLG 7 A in dichloromethane @100 mg/mL 3. PLA-PEG-Nic in dichloromethane @100 mg/mL 4. Polyvinyl alcohol @ 50 mg/mL in aqueous media Solution 1: PS-1826 CpG in aqueous solution was prepared by first dissolving PS-1826 into sterile, deionized, RNase/DNase-free water to final concentration of 100 mg/mL. Solution 2: PLGA 7525 DLG 7A @ 100 mg/mL in dichloromethane was prepared at room temperature and filtered with a 0.2 micron PTFE syringe filter. Solution 3: PLA-PEG-Nic @ 100 mg/mL in dichloromethane was prepared at room temperature and filtered with a 0.2 micron PTFE syringe filter. Solution 4: Polyvinyl alcohol @ 50 mg/mL was prepared in various aqueous media. Depending on the specific nanocarrier, the aqueous medium was either (a) 100 mM phosphate buffer pH 8, (b) purified water, or (c) 100 mM phosphate buffer pH 8 with 0.5M NaCl. A primary (Wl/O) emulsion was created using Solutions 1, 2, and 3. Solution 1 (0.1 ml) was added to 1 mL of a solution containing a 3:1 v:v ratio of Solution 2 (0.75 mL) and Solution 3 (0.25 mL) in a small glass pressure tube. The primary emulsion was formed by sonicating at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. The secondary (W1/0/W2) emulsion was then formed by adding Solution 4 (3.0 mL) to the primary emulsion and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250. The secondary emulsion was added to a stirring beaker containing 30 mL of an aqueous Solvent Evaportion (SE) medium. Depending on the specific nanocarrier, the medium was either (a and b) 70 mM phosphate buffer pH 8 or (c) 70 mM phosphate buffer pH 8 with 0.5M NaCl. The suspension was stirred at room temperature for 2 hours to allow the dichloromethane to evaporate and for the nanocarriers to form. A portion of the nanocarriers was washed by transferring the nanocarrier suspension to a centrifuge tube and spinning at 18,000 ref for 60 minutes, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. This washing procedure was repeated and then the 42 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 pellet was dispersed and re-suspended a final time in phosphate buffered saline for a final nanocarrier dispersion with nominal concentration of 10 mg/mL on a polymer basis.
The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method. The nanocarrier entrapped PS-1826 CpG loading (%w/w) and free PS-5 1826 content was determined by HPLC prior to washing and again after processing was complete. Mean effective particle size was determined by DLS.
The nanocarriers were produced in similar yields (91-98%) and similar mean effective diameter sizes (230-260nm). 10 Table 1
Nanocarrier Lot Wl, W2, PBS Osmolality (mOsm/kg) Unwashed PS-1826 Content Washed PS-1826 Content Entrapped (% w/w) Free (% w/w) Entrapped (% w/w) Free (% w/w) Lot X 330, 296, 276 6.1 3.7 6.8 0.1 LotY 330, 3, 276 5.0 5.7 5.8 0.0 Lot Z 330,1300, 276 7.3 2.8 6.9 0.9
Nanocarrier Lots X and Z were formed by a process that maintained a balanced near-physiologic osmolality (Lot X) or a transiently-elevated external phase osmolality (Lot Z) through to final dosage form. These nanocarriers had higher intermediate and final 15 loadings of the osmotic agent PS-1826 than the third nanocarrier lot (Lot Y) which had been formed with a low-osmolality W2 phase. Nanocarrier Lot Z is additionally characterized by the presence of significant free osmotically-active agent PS-1826, in the final dosage form. Forming the emulsion in a hypotonic outer media led to lower encapsulation. Creating a hypertonic external medium temporarily during processing led to transiently higher loads in 20 the particle. Once, however, the hypertonic media was replaced with isotonic media, the apparent advantage of hypertonicity was eliminated because the osmotic pressure gradient could not be effectively sustained
Example 2: Burst Studies 43 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
The nanocarriers of Example 1 were further evaluated for burst loss of entrapped PS-1826 CpG upon a cycle of freeze and thaw.
Method of freeze-thaw cycling: 0.5mL aliquots of the nanocarrier suspensions at approximately 7 mg 5 nanocarrier/mL from Example 1 were shelf-frozen at -20C in 1.7mL polypropylene centrifuge tubes. After overnight storage at -20C, the aliquots quickly transferred into a recirculating room-temperature water bath. The closed tubes were partially immersed in the in the stirred water bath such that the frozen portion in the tubes was fully below the water level. All the samples thawed within a few minutes but the aliquots were held in the bath 10 for 20 minutes before removal for prompt analysis of particle and supernatant analysis. As in Example 1, an HPLC-based content assay was performed to determine the nanocarrier-loaded and free PS-1826 content.
Table 2
Nanocarrier Theoretical Wl, W2, PBS Osmolality (mOsm/kg) Washed PS-1826 Content Post-F reeze/Thaw Content Entrapped (% w/w) Free (% w/w) Entrapped (% w/w) Free (% w/w) Lot X 330, 296, 276 6.8 0.1 5.1 1.6 LotY 330, 3, 276 5.8 0.0 3.9 1.3 Lot Z 330,1300, 276 6.9 0.9 6.9 0.7 15
Nanocarriers processed and finished in an isoosmotic system led to higher entrapment levels and resulted in reduced loss of content upon freeze and thaw. Some nanocarriers demonstrated 23% loss of entrapped PS-1826 to the media whereas others exhibited 0% loss. However, when the latter nanocarriers were subsequently pelleted and 20 transferred into fresh PBS buffer a 25% burst loss of oligonucleotide was observed. These data show the effect of a hypertonic medium in the external phase had only transient benefit and would not be helpful in the practice of the present invention due to potential side effects associated with administration of hypertonic dosage forms. 44 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
Example 3: Low osmolality suspension media can drive loss of immunostimulatory oligonucleotide from synthetic nanocarriers
Inventive osmotic mediated release barrier-free synthetic nanocarrier preparations were transferred (pelleted, resuspended) in various media to examine loading stability 5 through a freeze-thaw event.
To investigate the impact of various ionic media on the freeze/thaw stability of PS-1826 CpG containing nanocarriers, the following study was performed.
Inventive nanocarriers were made according to the method of Example 1, except that Solutions 2 & 3 were replaced with a single solution containing 100 mg/mL of PLGA-PEG-10 Nicotine in dichloromethane. The PLGA-PEG-Nicotine was synthesized and purified and had an approximate molecular weight of 80kD.
To transfer the nanocarriers to new media, aliquots of nanocarrier were pelleted by centrifugation (14,000 ref, 4C), the supemant was drawn off, replaced with an equal volume of new media, and the nanocarriers were resuspended. The process was performed twice on 15 each aliquot.
Retention of PS-1826 CpG during a freeze-thaw cycle was tested by shelf-freezing the aliquots at -20C in polypropylene centrifuge tubes, and then thawing by partial immersion in a stirred room-temperature water bath. The thawed materials were then analyzed by HPLC for free and pellet-loaded PS-1826 content. The free PS-1826 represents 20 loss of the entrapped osmotically-active agent from the nanocarrier. The buffers, calculated osmolality, and PS-1826 content and losses are tabulated below.
Table 3
Media* Osmolality (mOsm/kg) Lost PS-1826 (ug/ml) Retained PS-1826 (ug/ml) Loss (%) Isotonic saline (0.9% NaCl) 300 41.0 174.6 19 lOmM Potassium Phosphate 29.6 60.7 156.9 28 lOmM Ammonium Bicarbonate 21.9 58.0 154.7 27 lOmM Sodium Acetate 20.0 68.4 150.1 31 lOmM Sodium Carbonate 18.4 78.3 150.5 34 lOmM Glycine 10.1 78.5 145.2 35 45 PCT/US2012/030314
Endotoxin-free water 0 87.1 136.6 39 *Adjusted with counter-ion to pH of 7-8 before use. WO 2012/135010 2017203307 17 May 2017
The results did not trend with ionic species, but loss was greater for media with lower osmolality. 5
Example 4: Release rate of immunostimulatory oligonucleotide can be modulated by osmolality of the suspension media.
Inventive osmotic mediated release barrier-free synthetic nanocarriers were made at near-physiologic osmolality were transferred into various media at near neutral pH. The 10 resulting release profile were controlled by the osmolality of the media. Media at isotonic condition did not lead to release.
Materials PO-1826 DNA oligonucleotide with phosphodiester backbone having nucleotide 15 sequence 5'-TCC ATG ACG TTC CTG ACG TT-3' (SEQ ID NO: 1) with a sodium counter-ion was purchased from Oligo Factory (120 Jeffrey Ave., Holliston, MA 01746.) PLA with an inherent viscosity of 0.21 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, AL 35211. Product Code 100 DL 2A.) 20 PLA-PEG-Nicotine with a molecular weight of approximately 22,000 Da was synthesized using conventional methods.
Polyvinyl alcohol (Mw = 11,000 - 31,000, 87-89% hydrolyzed) was purchased from J.T. Baker (Part Number U232-08).
Solution 1: PO-1826 CpG in aqueous solution was prepared by first dissolving PO-25 1826 into sterile, deionized, RNase/DNase-free water to a concentration of 40 mg/mL.
Solution 2: PLA @ 75 mg/mL and PLA-PEG-nicotine @ 25 mg/ml in dichloromethane. The solution was prepared by combining two separate solutions at room temperature: PLA in dichloromethane and PLA-PEG-nicotine in dichloromethane, each filtered with a 0.2 micron PTFE syringe filter. The final solution was prepared by adding 3 30 parts PLA solution for each part of PLA-PEG-nicotine solution.
Solution 3: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer. 46 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
Solution 4: 70mM phosphate buffer pH 8 A primary (WI/O) emulsion was created using Solution 1 & Solution 2. Solution 1 (0.25 mL) and Solution 2 (1.0 mL) were combined in a small glass pressure tube and sonicated at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. 5 The secondary (W1/0/W2) emulsion was then formed by adding Solution 3 (3.0 mL) to the primary emulsion and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.
The second emulsion was added to a beaker containing Solution 4 (30mL) and stirred at room temperature for 2 hours to allow for the dichloromethane to evaporate and 10 for the nanocarriers to form. A portion of the nanocarriers were washed by transferring the nanocarrier suspension to a centrifuge tube and spinning at 21,000 ref for 45 minutes, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. This washing procedure was repeated and then the pellet was re-suspended in phosphate buffered saline for a final nanocarrier dispersion with nominal concentration of 10 mg/mL on a 15 polymer basis.
The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method. The PO-1826 CpG content of in the nanocarrier was determined by HPLC.
The in vitro release (IVR) rate in various media was determined by centrifugal 20 pelleting an aliquot of the nanocarrier and withdrawing the supernatant, resuspending the nanocarrier the new media, and incubating with agitation at 37C for 24 hours. PO-1826 CpG release was determined by HPLC at time of resuspension (t = 0 hours), 2 hours, 6 hours, and at 24 hours in the release media. Release was calculated as a percentage. The release media, burst release at time 0, and release over 24 hours is tabulated and graphed 25 below.
Table 4
Release Media & pH Calculated Osmolality (mOsm/kg) Burst Release (%) 24 hour Release (%) lOmM Phosphate + 150mM NaCl, pH 7.35 328 2 3 100 mM Phosphate, pH 7.5 275 18 25 lOmM Phosphate + 50mM 225 23 21 47 PCT/US2012/030314 EDTA lOmM Phosphate + 50mM NaCl, pH 7.35 128 22 32 lOmM Phosphate, pH 7.35 28 61 63 WO 2012/135010 2017203307 17 May 2017
Osmotic control of release is observed at physiologic pH (pH 7-8). As shown in the figure and table above, particles suspended in low-osmolality media (e.g., 28 mOsm/kg) quickly release entrapped active osmotic agent in significant amounts. As media with 5 increasingly higher osmolality are used (with either NaCl, sodium phosphate, and/or EDTA used to establish osmolality), the percent release at T = 0 h and 24 h is reduced correspondingly. Near-zero release of the osmotic agent into media of physiologic-osmolality and physiologic pH indicates the stability of the nanocarrier in a preparation suitable for administration. 10
Example 5: Nicotine Vaccination Experiments
Osmotic-mediated release synthetic nanocarriers may be formulated with sensitivity to pH at near-physiologic osmolality. The release rate of the active osmotic agent as a function of pH may relate to the potency of pharmacologic effect. The objectives of the two 15 experiments detailed below were twofold: (1) to confirm that more potent nanocarriers were achieved with the same nanocarrier materials and formation methods when the selection of media was designed to not expose the nanocarriers to prolonged osmotic gradients of greater than approximately 140 mOsm/kg (calculated as nanocarrier-phase osmolality minus average system osmolality including suspension media) and (2) to evaluate the relationship 20 between in-vitro release rates in acidic media of a CpG adjuvant from nanocarriers to their potency. Potency in both cases is measured in terms of the levels of of antibodies induced by the adjuvant-loaded antigen-presenting nanocarriers.
Nanoparticle Formulation and IVR determination 25
Materials 48 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 PO-1826 DNA oligonucleotide with phosphodiester backbone having nucleotide sequence 5'-TCC ATG ACG TTC CTG ACG TT-3' (SEQ ID NO: 1) with a sodium counter-ion was purchased from Oligo Factory (120 Jeffrey Ave., Holliston, MA 01746.) Ovalbumin peptide 323-339, a 17 amino acid peptide known to be a T and B cell epitope of 5 Ovalbumin protein, was purchased from Bachem Americas Inc. (3132 Kashiwa Street, Torrance CA 90505. Part # 4065609.) PLA with an inherent viscosity of 0.21 dL/g was purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, AL 35211. Product Code 100 DL 2A.) PLGA with varied inherent viscosities (IV) and lactide:glycolide (L:G) ratios were 10 purchased from SurModics Pharmaceuticals (756 Tom Martin Drive, Birmingham, AL 35211.) or Boehringer Ingelheim (55216 Ingelheim am Rhein, Germany). The product codes, manufacturer, IV, and L:G ratios were as tabulated below.
Table 5
Product code Manufacturer IV (dL/g) L:G ratio 5050 DLG Surmodics 0.25 52:48 2.5A RG653H Boehringer Ingelheim 0.3 65:35 7525 DLG 7A Surmodics 0.75 75:25 PLA-PEG-Nicotine with a molecular weight of approximately 22,000 Da was synthesized using conventional methods. Polyvinyl alcohol (Mw = 11,000 - 31,000, 87-89% hydrolyzed) was purchased from J.T. Baker (Part Number U232-08). 20 Method for Synthetic Nanocarrier Lot A (MHCII peptide nanocarrier)
Solution 1: Ovalbumin peptide 323 - 339 @ 40 mg/mL in 0.13N hydrochloric acid (HC1). The solution was prepared by dissolving ovalbumin peptide directly in 0.13N HC1 solution at room temperature and then filtering with a 0.2 micron PES syringe filter.
Solution 2: 0.21-IV PLA @ 75 mg/mL and PLA-PEG-nicotine @ 25 mg/ml in 25 dichloromethane. The solution was prepared by first making two separate solutions at room temperature: 0.21-IV PLA @ 100 mg/mL in pure dichloromethane and PLA-PEG-nicotine 49 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 @100 mg/mL in pure dichloromethane, each filtered with a 0.2 micron PTFE syringe filter. The final solution was prepared by adding 3 parts PLA solution for each part of PLA-PEG-nicotine solution.
Solution 3: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer. 5 Solution 4: 70mM phosphate buffer pH 8 A primary (WI/O) emulsion was created using Solution 1 & Solution 2. Solution 1 (0.2 mL) and Solution 2 (1.0 mL) were combined in a small glass pressure tube and sonicated at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250.
The secondary (W1/0/W2) emulsion was then formed by adding Solution 3 (3.0 mL) to the 10 primary emulsion and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.
The second emulsion was added to a beaker containing 70mM phosphate buffer solution (30 mL) and stirred at room temperature for 2 hours to allow for the dichloromethane to evaporate and for the nanocarriers to form. A portion of the nanocarriers 15 were washed by transferring the nanocarrier suspension to a centrifuge tube and spinning at 21,000 ref for 45 minutes, removing the supernatant, and re-suspending the pellet in phosphate buffered saline. This washing procedure was repeated and then the pellet was resuspended in phosphate buffered saline for a final nanocarrier dispersion with nominal concentration of 10 mg/mL on a polymer basis. 20 The total dry-nanocarrier mass per mL of suspension was determined by a gravimetric method. The peptide content of the nanocarrier was determined by HPLC to be 4.1% w/w. The nanocarrier concentration was diluted to 5 mg/mL before use by adding phosphate buffered saline. 25 Method for Nanocarrier lots B, C, l), E, F, &G (CpG-containing nanocarriers)
Solution 1: PO-1826 CpG in aqueous solution was prepared by first dissolving PO-1826 into sterile, deionized, RNase/DNase-free water to make a concentrated stock solution (e.g., 200 mg/mL). The solution was diluted to 40 mg/mL with either additional water or with an aqueous KC1 solution. The final solution 1 media used to make each synthetic 30 nanocarrier lot are tabulated below.
Table 6 50 WO 2012/135010 2017203307 17 May 2017 PCT/US2012/030314
Nanocarrier Lot Solution 1 medium Solution 1 Calculated Osmolality (mOsm/kg) B 150 mM KC1 432 C Water 132 D Water 132 E Water 132 L 125 mM KC1 382 G 125 mM KC1 382 H 150 mM KC1 432
Solution 2: PLGA @75 mg/mL and PLA-PEG-nicotine @ 25 mg/ml in dichloromethane. The solution was prepared by combining two separate solutions at room temperature: PLGA in dichloromethane and PLA-PEG-nicotine in dichloromethane, each 5 filtered with a 0.2 micron PTLE syringe filter. The final solution was prepared by adding 3 parts PLA solution for each part of PLA-PEG-nicotine solution. The PLGA composition used to prepare each nanocarrier is tabulated below. In the case of Lot E, the dichloromethane additional included 5% v/v benzyl alcohol, which was found to reduce PO-1826 entrapment efficiency yet maintain an intermediate rate of PO-1826 release. 10
Table 7
Nanocarrier Lot PLGA Source B 7525 DLG 7A C 7525 DLG 7A : 5050 DLG 2.5A @ 2:1 weight ratio D 7525 DLG 7A E 7525 DLG 7A L RG653H G 7525 DLG 7A H 7525 DLG 7A : 5050 DLG 2.5A @ 2:1 weight ratio 51 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017
Solution 3: Polyvinyl alcohol @ 50 mg/mL in 100 mM pH 8 phosphate buffer (calculated solution osmolality 298 mOsm/kg). In the case of Lot D the phosphate buffer was replaced with 150 mM KC1 (calculated solution osmolality 304 mOsm/kg).
Solution 4: 70mM phosphate buffer pH 8 (calculated solution osmolality 206 5 mOsm/kg). In the case of S0890-09-7 solution 4 was purified water (effectively zero osmolality). A primary (W I/O) emulsion was created using Solution 1 & Solution 2. Solution 1 (0.25 mL) and Solution 2 (1.0 ml) were combined in a small glass pressure tube and sonicated at 50% amplitude for 40 seconds using a Branson Digital Sonifier 250. 10 The secondary (W1/0/W2) emulsion was then formed by adding Solution 3 (3.0 mL) to the primary emulsion and sonicating at 30% amplitude for 60 seconds using the Branson Digital Sonifier 250.
The second emulsion was added to a beaker containing Solution 4 (30mL) and stirred at room temperature for 2 hours to allow for the dichloromethane to evaporate and 15 for the synthetic nanocarriers to form. A portion of the synthetic nanocarriers were washed by transferring the synthetic nanocarrier suspension to a centrifuge tube and spinning at 21,000 ref for 45 minutes, removing the supernatant, and re-suspending the pellet in fresh
Solution 4. This washing procedure was repeated and then the pellet was resuspended in phosphate buffered saline for a final synthetic nanocarrier dispersion with 20 nominal concentration of 10 mg/mL on a polymer basis.
The total dry synthetic nanocarrier mass per mL of suspension was determined by a gravimetric method. The PO-1826 CpG content of the synthetic nanocarriers was determined by HPLC. The synthetic nanocarrier concentration was diluted to 5 mg/mL before use by adding phosphate buffered saline. 25 The in vitro release (IVR) rate was determined by centrifugal pelleting an aliquot of the synthetic nanocarriers, resuspending the synthetic nanocarriers in 100 mM pH 4.5 citrate buffer, and incubating with agitation at 37C for 24 hours. PO-1826 CpG release was determined by HPLC at time of resuspension (t = 0 hours), at 6hours, and at 24 hours in the release media. The IVR was calculated by subtracting the tO release from the 24-hour 30 release, and normalizing per synthetic nanocarrier mass. PO-1826 CpG load and IVR (24h-Oh) for the synthetic nanocarriers is tabulated below. 52 WO 2012/135010 2017203307 17 May 2017
Table 8 PCT/U S2012/030314
Nanocarrier Lot Max. outward-directed osmotic gradient (mOsm/kg) PO-1826 Load (% w/w) IVR (24h-0h) ug-CpG/mg-NC B 134 7.5 13 C 79 7.0 22 D 291 4.6 3 E 79 4.9 9 F 98 9.0 31 G 98 8.8 18 H 134 6.6 25
Nanocarrier D demonstrates the load-reducing impact of processing with a high outward-directed osmotic gradient resulting from the use of purified water as the solvent-5 evaporation medium having osmolality significantly less than 200 mOsm/kg. The 4.6% load of CpG in nanocarrier D is reduced compared in particular to nanocarriers B and G, which have the same polymeric composition. The reduced loading of nanocarrier D is also associated with a reduced IVR as measured in acidic medium. 10 Vaccination
Naive C57BL/6 female mice, 5 animals per nanoparticle group, were inoculated with nicotine vaccine nanoparticles. Inoculations were made subcutaneously into the hind pads of naive C57BL/6 females (5 animals per group) according to a schedule of a prime on day 0 followed by boosts on days 14 and 28. For each inoculation a total of 100 pg 15 nanocarrier (NC) was injected, divided equally between the hind limbs. Planned sera collection and analysis for anti-nicotine antibody titers were performed at days 26 and 40. Anti-nicotine IgG antibody titers were measured by ELISA and are reported as EC50 values.
Each animal received inoculations that contained a 1:1 mixture of two different 20 nanocarriers; one providing an MHC II peptide (Lot A), a second providing a CpG adjuvant (Lots B-G). Both particles presented nicotine. The same lot of MHC II peptide-containing nanocarrier, Lot A, was used in all groups. The CpG-containing nanocarrier was different 53 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 for each group (i.e. different lots were used). The CpG-containing nanocarriers differed in their PLGA composition and CpG loading, leading to different in vitro release (IVR) rates of CpG into an acidic medium. In the case of nanocarrier E, the release rate was also affected by the use of benzyl alcohol in the nanocarrier formation process. 5 The CpG nanocarrier and IVR are presented for each group along with the resulting anti-nicotine antibody titer (mean EC50 and standard deviation) at day 40 (Tables 9 & 2=10).
Study 1 directly compared the potency of the CpG-containing nanocarrier lots B, C, D, and E. As tabulated below, there was a direct relationship between the release rate in 10 acidic medium and the resulting peak (day 40) titers.
Table 9
CpG Nanocarrier Net 24h IVR (pg/mg-NP) Anti-Nicotine Antibody Titer (EC5o) C 22 891,000 B 13 278,000 E 9 260,000 D 3 99,000
Three of the four nanocarriers of the above example were prepared with control of 15 osmotic gradients to limit CpG losses during processing and storage. Nanocarrier group D had reduced load and IVR due to the significant gradient introduced during a processing step, and the impact can be seen in the potency of anti-nicotine antibody generation. While nanocarriers of groups B and D were made of the same materials, vaccination with the group D nanocarriers resulted in approximately 1/3 the titer generation. 20 Further evident in the study is the value that can be created by modulating the composition of the osmotic barrier-free synthetic nanocarriers such that pH-influence on release is adjusted. The pH triggered osmotic mediated release barrier-free synthetic nanocarriers having greater acidic sensitivity (higher acidic-IVR of the CpG adjuvant) generated higher antibody titers to the target antigen.
25 The relationship of increasing titer with increasing acidic-medium IVR (per the IVR protocol above) was repeated in a follow-up study (Study 2). pH triggered osmotic 54 PCT/US2012/030314 WO 2012/135010 2017203307 17 May 2017 mediated release barrier-free synthetic CpG-containing nanocarriers lots F, H, C, and G were evaluated in a head-to-head anti-nicotine vaccination study. As with study 1, the results tabulated below demonstrate increasing in vivo potency with increasing IVR in an acidic medium. 5
Table 10
CpG Nanocarrier Net 24h IVR (pg/mg-NP) Anti-Nicotine Antibody Titer (EC5o) F 31 565,000 H 25 397,000 C 22 377,000 G 18 221,000
In all instances, the osmotic barrier-free nanocarriers were processed and handled to avoid outward-directed gradients that would significantly reduce the load of the entrapped 10 osmotically-active agent, CpG. This process and formulation approach again enabled the modulation of acidic-IVR rates through polymeric composition. As with the previous example, within the range of IVR evaluated, higher rates of CpG release resulted in greater potency as evidenced by the antigen-specific antibody titers. 55
Claims (51)
- What is claimed is:1. A dosage form comprising: osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers comprising an encapsulated osmotically active agent.
- 2. The dosage form of claim 1, further comprising a vehicle having an osmolality of 200-500 mOsm/kg.
- 3. A lyophilized dosage form comprising: lyophilized osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers comprising an encapsulated osmotically active agent; and lyophilizing agents that provide a vehicle having an osmolality of 200-500 mOsm/kg upon reconstitution of the lyophilized dosage form.
- 4. The dosage form of claim 3, wherein the lyophilizing agents comprise salts and buffering agents, simple or complex carbohydrates, polyols, pH adjustment agents, chelating and antioxidant agents, stabilizers and preservatives, or surfactants.
- 5. The dosage form of claim 4, wherein the salts and buffering agents comprise NaCl, NaPC>4, or Tris, the simple or complex carbohydrates comprise sucrose, dextrose, dextran, or carboxymethyl cellulose, the polyols comprise mannitol, sorbitol, glycerol, or polyvinyl alcohol, the pH adjustment agents comprise HC1, NaOH, or sodium citrate, the chelating and antioxidant agents comprise EDTA, ascorbic acid, or alpha-tocopherol, the stabilizers and preservatives comprise gelatin, glycine, histidine, or benzyl alcohol, and/or the surfactants comprise polysorbate 80, or sodium deoxycholate.
- 6. The dosage form of any of claims 1 to 5, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 2 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 7. The dosage form of claim 6, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 3 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 8. The dosage form of claim 7, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 4 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 9. The dosage form of claim 8, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 5 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 10. The dosage form of claim 9, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 6 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 11. The dosage form of claim 10, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 7 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 12. The dosage form of claim 11, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 8 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 13. The dosage form of any of claims 1-12, wherein the osmotically active agent comprises an isolated nucleic acid, a polymer, an isolated peptide, an isolated saccharide, macrocycle, or ions, cofactors, coenzymes, ligands, hydrophobically-paired agents, or hydrogen-bond donors or acceptors of any of the above.
- 14. The dosage form of claim 13, wherein the isolated nucleic acid comprises: an immunostimulatory nucleic acid, immunostimulatory oligonucleotides, small interfering RNA, RNA interference oligonucleotides, RNA activating oligonucleotides, micro RNA oligonucleotides, antisense oligonucleotides, aptamers, gene therapy oligonucleotides, natural form plasmids, non-natural plasmids, chemically modified plasmids, chimeras that include oligonucleotide-based sequences, and combinations of any of the above.
- 15. The dosage form of claim 13, wherein the polymer comprises osmotically active: dendrimers, polylactic acids, polyglycolic acids, poly lactic-co-glycolic acids, polycaprolactams, polyethylene glycols, polyacrylates, polymethacrylates, and co-polymers and/or combinations of any of the above.
- 16. The dosage form of claim 13, wherein the isolated peptide comprises osmotically active: immunomodulatory peptides, MHC Class I or MHC Class II binding peptides, antigenic peptides, hormones and hormone mimetics, ligands, antibacterial and antimicrobial peptides, anti-coagulation peptides, and enzyme inhibitors.
- 17. The dosage form of claim 13, wherein the isolated saccharide comprises osmotically active: antigenic saccharides, lipopolysaccharides, protein or peptide mimetic saccharides, cell surface targeting saccharides, anticoagulants, anti-inflammatory saccharides, antiproliferative saccharides, including their natural and modified forms, monosaccharides, disaccharides, trisaccharides, oligosaccharides, or polysaccharides.
- 18. The dosage form of any one of claims 1-17, wherein the osmotically active agent comprises an antigen, adjuvant, or immunostimulatory or immunomodulatory substance.
- 19. The dosage form of any of claims 1-18, wherein the osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers comprise pH triggered osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers.
- 20. The dosage form of any of claims 1-19, wherein the osmotic gradient of the dosage form is 140 mOsm/kg or less.
- 21. A method comprising: providing osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers that comprise an osmotically active agent in an environment having an osmolality ranging from 200-500 mOsm/kg; and administering the osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers to a subject.
- 22. The method of claim 21, wherein the osmotic gradient between the nanocarrier phase and the environment is 140 mOsm/kg or less.
- 23. The method of claim 21 or 22, further comprising: processing the formed osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers in an environment having an osmolality ranging from 200500 mOsm/kg.
- 24. The method of claim 23, wherein processing comprises: washing the synthetic nanocarriers, centrifuging the synthetic nanocarriers, filtering the synthetic nanocarriers, concentrating or diluting the synthetic nanocarriers, freezing the synthetic nanocarriers, drying or lyophilizing the synthetic nanocarriers, combining the synthetic nanocarriers with other synthetic nanocarriers or with additive agents or excipients, adjusting the pH or buffer environment of the synthetic nanocarriers, entrapping the synthetic nanocarriers in a gel or high-viscosity medium, resuspending the synthetic nanocarriers, surface modifying the synthetic nanocarriers covalently or by physical processes such as coating or annealing, impregnating or doping the synthetic nanocarriers with active agents or excipients, sterilizing the synthetic nanocarriers, reconstituting the synthetic nanocarriers for administration, or combinations of any of the above.
- 25. The method of any one of claims 21-24, further comprising storing the formed osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg.
- 26. The method of any one of claims 21-25, further comprising formulating the formed osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers into a dosage form that maintains the formed osmotic mediated release barrier-free, double emulsion polymeric synthetic nanocarriers in an environment having an osmolality ranging from 200-500 mOsm/kg.
- 27. The method of any one of claims 21-26, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 2 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 28. The method of claim 27, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 3 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 29. The method of claim 28, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 4 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 30. The method of claim 29, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 5 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 31. The method of claim 30, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 6 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 32. The method of claim 31, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 7 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 33. The method of claim 32, wherein the osmotically active agent is present in the synthetic nanocarriers in an amount of about 8 weight percent, based on the total theoretical weight of the synthetic nanocarriers.
- 34. The method of any one of claims 21-33, wherein the osmotically active agent comprises an isolated nucleic acid, a polymer, an isolated peptide, an isolated saccharide, macrocycle, or ions, cofactors, coenzymes, ligands, hydrophobically-paired agents, or hydrogen-bond donors or acceptors of any of the above.
- 35. The method of claim 34, wherein the isolated nucleic acid comprises: an immunostimulatory nucleic acid, immunostimulatory oligonucleotides, small interfering RNA, RNA interference oligonucleotides, RNA activating oligonucleotides, micro RNA oligonucleotides, antisense oligonucleotides, aptamers, gene therapy oligonucleotides, natural form plasmids, non-natural plasmids, chemically modified plasmids, chimeras that include oligonucleotide-based sequences, and combinations of any of the above.
- 36. The method of claim 34, wherein the polymer comprises osmotically active: dendrimers, polylactic acids, polyglycolic acids, poly lactic-co-glycolic acids, polycaprolactams, polyethylene glycols, polyacrylates, polymethacrylates, and co-polymers and/or combinations of any of the above.
- 37. The method of claim 34, wherein the isolated peptide comprises osmotically active: immunomodulatory peptides, MHC Class I or MHC Class II binding peptides, antigenic peptides, hormones and hormone mimetics, ligands, antibacterial and antimicrobial peptides, anti-coagulation peptides, and enzyme inhibitors.
- 38. The method of claim 34, wherein the isolated saccharide comprises osmotically active: antigenic saccharides, lipopolysaccharides, protein or peptide mimetic saccharides, cell surface targeting saccharides, anticoagulants, anti-inflammatory saccharides, antiproliferative saccharides, including their natural and modified forms, monosaccharides, disaccharides, trisaccharides, oligosaccharides, or polysaccharides.
- 39. The method of any one of claims 21-38, wherein the osmotically active agent comprises an antigen, adjuvant, or immunostimulatory or immunomodulatory substance.
- 40. A method of administering to a subject in need thereof the dosage form of any one of claims 1-20.
- 41. The method of any one of claims 21-40, wherein the synthetic nanocarriers or dosage form is/are in an amount effective to modulate, for example, induce, enhance, suppress, direct, or redirect, an immune response.
- 42. The method of any one of claims 21-41, wherein the subject has cancer, an infectious disease, a metabolic disease, a degenerative disease, an autoimmune disease, an inflammatory disease, an immunological disease, an addiction, or a condition resulting from the exposure to a toxin, hazardous substance, environmental toxin, or other harmful agent.
- 43. A kit, comprising the dosage form of any one of claims 1-20.
- 44. The kit of claim 43, further comprising instructions for use and/or mixing.
- 45. The kit of claim 43 or 44, further comprising an agent for reconstitution or a pharmaceutically acceptable carrier.
- 46. A dosage form as defined in any one of claims 1-20 for use in therapy or prophylaxis.
- 47. A dosage form or synthetic nanocarriers as defined in any one of claims 1-20 for use in a method as defined in any one of claims 21-42.
- 48. A dosage form as defined in any one of claims 1-20 for use in a method of modulating, for example, inducing, enhancing, suppressing, directing, or redirecting, an immune response.
- 49. A dosage form as defined in any one of claims 1-20 for use in a method of treating or preventing cancer, an infectious disease, a metabolic disease, a degenerative disease, an autoimmune disease, an inflammatory disease, an immunological disease, an addiction, or a condition resulting from the exposure to a toxin, hazardous substance, environmental toxin, or other harmful agent.
- 50. A dosage form as defined in any one of claims 1-20 for use in a method of therapy or prophylaxis comprising administration by a subcutaneous, intramuscular, intradermal, oral, intranasal, transmucosal, sublingual, rectal, ophthalmic, transdermal, transcutaneous route or by a combination of these routes.
- 51. Use of the dosage form or synthetic nanocarriers as defined in any one of claims 1 -20 for the manufacture of a medicament for use in a method as defined in any one of claims 2142 or 48-50.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2017203307A AU2017203307A1 (en) | 2011-03-25 | 2017-05-17 | Osmotic mediated release synthetic nanocarriers |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161467595P | 2011-03-25 | 2011-03-25 | |
US61/467,595 | 2011-03-25 | ||
AU2012236937A AU2012236937B2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
PCT/US2012/030314 WO2012135010A2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
AU2017203307A AU2017203307A1 (en) | 2011-03-25 | 2017-05-17 | Osmotic mediated release synthetic nanocarriers |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012236937A Division AU2012236937B2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2017203307A1 true AU2017203307A1 (en) | 2017-06-08 |
Family
ID=46877545
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012236937A Active AU2012236937B2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
AU2017203307A Abandoned AU2017203307A1 (en) | 2011-03-25 | 2017-05-17 | Osmotic mediated release synthetic nanocarriers |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2012236937A Active AU2012236937B2 (en) | 2011-03-25 | 2012-03-23 | Osmotic mediated release synthetic nanocarriers |
Country Status (11)
Country | Link |
---|---|
US (2) | US20120244222A1 (en) |
EP (1) | EP2694040A4 (en) |
JP (2) | JP6320912B2 (en) |
KR (1) | KR20140022025A (en) |
CN (1) | CN103458879A (en) |
AU (2) | AU2012236937B2 (en) |
BR (1) | BR112013024655A2 (en) |
CA (1) | CA2830948A1 (en) |
EA (1) | EA201391392A1 (en) |
MX (1) | MX366228B (en) |
WO (1) | WO2012135010A2 (en) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA022699B1 (en) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
EP3311833A3 (en) * | 2009-08-26 | 2018-07-25 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
EA023397B1 (en) | 2010-05-26 | 2016-05-31 | Селекта Байосайенсиз, Инк. | Synthetic nanocarrier combination vaccines |
WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012149259A1 (en) | 2011-04-29 | 2012-11-01 | Selecta Biosciences, Inc. | Tolerogenic synthetic nanocarriers to reduce antibody responses |
AU2012290306B2 (en) | 2011-07-29 | 2017-08-17 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
AU2013243946A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
AU2013243949A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EA201592103A3 (en) | 2013-05-03 | 2016-08-31 | Селекта Байосайенсиз, Инк. | METHODS AND COMPOSITIONS FOR STRENGTHENING CD4 + REGULATORY T-CELLS |
US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
AU2014351482B2 (en) | 2013-11-22 | 2020-08-20 | Mina Therapeutics Limited | C/EBP alpha short activating RNA compositions and methods of use |
WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
CN106714826A (en) | 2014-09-07 | 2017-05-24 | 西莱克塔生物科技公司 | Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses |
KR101646181B1 (en) | 2015-08-18 | 2016-08-05 | 한양대학교 에리카산학협력단 | Composition of irinotecan-loaded dual-reverse thermosensitive hydrogel |
LT3394093T (en) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Methods of using ox40 ligand encoding polynucleotides |
MA43587A (en) | 2016-01-10 | 2018-11-14 | Modernatx Inc | THERAPEUTIC RNA CODING FOR ANTI-CTLA-4 ANTIBODIES |
AR108280A1 (en) * | 2016-05-05 | 2018-08-08 | Acraf | OPHTHALM COMPOSITION THAT INCLUDES A SYNERGIC COMBINATION OF GLUCOGEN AND Hyaluronic Acid OR SALT OF THE SAME |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
JP2020501545A (en) | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | RNA for treatment or prevention of liver disease |
CN110612122A (en) | 2017-03-11 | 2019-12-24 | 西莱克塔生物科技公司 | Methods and compositions related to combination therapy with anti-inflammatory agents and synthetic nanocarriers comprising immunosuppressants |
EP3679138B1 (en) | 2017-09-08 | 2023-03-22 | MiNA Therapeutics Limited | Hnf4a sarna compositions and methods of use |
US20200208152A1 (en) | 2017-09-08 | 2020-07-02 | Mina Therapeutics Limited | Stabilized sarna compositions and methods of use |
JP2021501753A (en) * | 2017-11-03 | 2021-01-21 | ザ・トラスティーズ・オブ・プリンストン・ユニバーシティThe Trustees Of Princeton University | Hydrophobic ion pairing and flash nanoprecipitation to form sustained release nanocarrier formulations |
WO2019197845A1 (en) | 2018-04-12 | 2019-10-17 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
JP2021534101A (en) | 2018-08-09 | 2021-12-09 | ヴェルソー セラピューティクス, インコーポレイテッド | Oligonucleotide compositions for targeting CCR2 and CSF1R and their use |
US20220211740A1 (en) | 2019-04-12 | 2022-07-07 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
CN114391040A (en) | 2019-09-23 | 2022-04-22 | 欧米茄治疗公司 | Compositions and methods for modulating apolipoprotein B (APOB) gene expression |
US11987791B2 (en) | 2019-09-23 | 2024-05-21 | Omega Therapeutics, Inc. | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (HNF4α) gene expression |
JP2023517326A (en) | 2020-03-11 | 2023-04-25 | オメガ セラピューティクス, インコーポレイテッド | Compositions and methods for modulating forkhead box P3 (FOXP3) gene expression |
GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
US20240175033A1 (en) | 2021-03-26 | 2024-05-30 | Mina Therapeutics Limited | TMEM173 saRNA Compositions and Methods of Use |
EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
WO2023161350A1 (en) | 2022-02-24 | 2023-08-31 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5186941A (en) * | 1983-05-06 | 1993-02-16 | Vestar, Inc. | Vesicle formulation for the controlled release of therapeutic agents |
US4855132A (en) * | 1986-02-25 | 1989-08-08 | S R I International | Method of preparing bioerodible polymers having pH sensitivity in the acid range and resulting product |
US5993850A (en) * | 1994-09-13 | 1999-11-30 | Skyepharma Inc. | Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances |
US6106858A (en) * | 1997-09-08 | 2000-08-22 | Skyepharma, Inc. | Modulation of drug loading in multivescular liposomes |
IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
GB0009735D0 (en) * | 2000-04-19 | 2000-06-07 | Zeneca Ltd | Formulation |
CA2313659A1 (en) * | 2000-07-06 | 2002-01-06 | Barry J. Barclay | B complex vitamin compositions that protect against cellular damage caused by ultraviolet light |
DE60118228T2 (en) * | 2000-09-28 | 2006-12-14 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | MICROPARTICLES FOR THE ADMINISTRATION OF HETEROLOGIC NUCLEIC ACID |
US20030215394A1 (en) * | 2002-05-17 | 2003-11-20 | Short Robert E. | Microparticles having a matrix interior useful for ultrasound triggered delivery of drugs into the bloodstream |
JP4038585B2 (en) * | 2002-06-03 | 2008-01-30 | 宮崎県 | Solid fat microcapsule and method for producing the same |
US7060299B2 (en) * | 2002-12-31 | 2006-06-13 | Battelle Memorial Institute | Biodegradable microparticles that stabilize and control the release of proteins |
US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
EP1679065A1 (en) * | 2005-01-07 | 2006-07-12 | OctoPlus Sciences B.V. | Controlled release compositions for interferon based on PEGT/PBT block copolymers |
US20080305161A1 (en) * | 2005-04-13 | 2008-12-11 | Pfizer Inc | Injectable depot formulations and methods for providing sustained release of nanoparticle compositions |
US8765181B2 (en) * | 2005-09-09 | 2014-07-01 | Beijing Diacrid Medical Technology Co., Ltd | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids |
US9393215B2 (en) * | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
DE102006013531A1 (en) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Drug delivery system, useful for supplying active substance to central nervous system of a mammal over the blood-brain barrier, comprises: nanoparticles of poly(DL-lactide-co-glycolide) and pharmaceutical substance e.g. cytostatic agent |
CN101965212A (en) * | 2007-12-05 | 2011-02-02 | 眼门药品公司 | Methods for delivering sirna via ionthophoresis |
US8815253B2 (en) * | 2007-12-07 | 2014-08-26 | Novartis Ag | Compositions for inducing immune responses |
FR2935901A1 (en) * | 2008-09-16 | 2010-03-19 | Inst Curie | STIMULABLE ASYMMETRIC POLYMERSOME. |
EA022699B1 (en) * | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
ES2769357T3 (en) * | 2009-06-16 | 2020-06-25 | Pfizer | Pharmaceutical forms of apixaban |
-
2012
- 2012-03-23 EA EA201391392A patent/EA201391392A1/en unknown
- 2012-03-23 US US13/428,340 patent/US20120244222A1/en not_active Abandoned
- 2012-03-23 EP EP12764409.4A patent/EP2694040A4/en active Pending
- 2012-03-23 BR BR112013024655A patent/BR112013024655A2/en not_active Application Discontinuation
- 2012-03-23 CA CA2830948A patent/CA2830948A1/en not_active Abandoned
- 2012-03-23 JP JP2014502642A patent/JP6320912B2/en active Active
- 2012-03-23 MX MX2013010972A patent/MX366228B/en active IP Right Grant
- 2012-03-23 AU AU2012236937A patent/AU2012236937B2/en active Active
- 2012-03-23 KR KR1020137027777A patent/KR20140022025A/en not_active Application Discontinuation
- 2012-03-23 WO PCT/US2012/030314 patent/WO2012135010A2/en active Application Filing
- 2012-03-23 CN CN2012800146549A patent/CN103458879A/en active Pending
-
2017
- 2017-05-17 AU AU2017203307A patent/AU2017203307A1/en not_active Abandoned
- 2017-12-01 JP JP2017231391A patent/JP2018076331A/en active Pending
-
2022
- 2022-07-28 US US17/815,877 patent/US20230139671A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2694040A4 (en) | 2014-09-03 |
CA2830948A1 (en) | 2012-10-04 |
MX366228B (en) | 2019-07-03 |
US20230139671A1 (en) | 2023-05-04 |
WO2012135010A2 (en) | 2012-10-04 |
KR20140022025A (en) | 2014-02-21 |
AU2012236937B2 (en) | 2017-06-08 |
MX2013010972A (en) | 2013-12-06 |
JP2018076331A (en) | 2018-05-17 |
CN103458879A (en) | 2013-12-18 |
US20120244222A1 (en) | 2012-09-27 |
EP2694040A2 (en) | 2014-02-12 |
JP6320912B2 (en) | 2018-05-09 |
BR112013024655A2 (en) | 2016-12-20 |
WO2012135010A3 (en) | 2012-11-22 |
EA201391392A1 (en) | 2014-04-30 |
AU2012236937A1 (en) | 2013-09-19 |
JP2014511847A (en) | 2014-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230139671A1 (en) | Osmotic mediated release synthetic nanocarriers | |
US9764031B2 (en) | Dose selection of adjuvanted synthetic nanocarriers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |